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Abstract
In this thesis I examine several ways of extracting information from wearable monitors
so as to help make clinical decisions. Wearable physiological sensors are developing
rapidly, and pose a possible part of the solution to the demands of an aging population
and rising health care costs. It is important that the data produced by such sensors
be processed into information that is clinically relevant and will have an impact on
the practice of medicine. I collected data in an ambulatory setting from several wear-
able physiological sensors, including electrocardiogram, arterial blood pressure, pulse
plethysmograph, respiration and acceleration. Using this data set, I demonstrated
a few approaches - including signal processing, and algorithms based on the appli-
cation of physiological models - to extract clinically relevant information. These
approaches are potentially of interest to both device makers interested in developing
wearable monitors, and to clinicians who will be using such monitors in the future.
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Chapter 1
Introduction
This chapter puts forth the motivation for undertaking the study described in this
thesis. I describe the goals of the project and the constraints on these goals. I then
delineate my contributions specifically and give an outline of the document.
1.1 Motivation
.Wearable medical monitors hold the promise of widespread use at low costs. Until
now, such devices have been rudimentary and limited in their applications. Recent
advances in integrated circuit technology have led to energy efficient, miniaturized
devices suitable for long-term wearable use. Such technology has also led to lower
costs, which is critical at the current time when concern for health care costs is
rapidly growing. Despite being a possible inexpensive and ubiquitous solution for a
variety of medical conditions, clinical adoption faces several challenges. Raw data
from such devices may not be intuitive to a clinician and the large volume of data
may render it useless. For example, most physicians do not look at the shape of
blood pressure waveforms, but rather observe systolic, diastolic and mean values. It
would also be impossible to fit a very long stretch of data into one plot and still be
able to observe waveform shape. This work focuses on bridging the gap between the
raw data recorded from wearable medical monitors and information provided to a
clinician that can positively influence diagnosis and treatment of patients.
1.2 Scope of Project
The first step of this project was to collect data from a prototype cardiac monitoring
device that includes a single-lead ECG and a 3-axis accelerometer. Additionally, a su-
perset of physiologic data was collected with a variety of wearable and clinical sensors
including an ECG, respiration, pulse plethysmograph and arterial blood pressure. It
is reasonable to assume that such sensors could be packaged in a wearable form factor
in the near future. The ultimate goal of such devices is to have them incorporated
into routine clinical practice, so the data collected must be presented to clinicians in
a way that they can act on. My task was to convert the raw data collected during
our study into clinically relevant information.
1.3 Contributions
I started on this project designing the data collection setup and making arrangements
at the Clinical Research Center at MIT where the experiments were conducted. I then
supervised the data collection in conjunction with the study nurse and another mem-
ber of our research group. I suggested modifications to improve the device software
and protocol, ensuring higher quality data collection. I archived the data for process-
ing and annotated much of it for further processing. I then sorted through the data
and applied algorithms and models to derive clinically relevant information from the
raw data.
1.4 Outline
The document starts with a background of physiology, technology for recording phys-
iology (exercise physiology specifically) and what tests are used clinically. In Chapter
3, I explain the data collection setup and how the experiments were carried out. The
data chapter (Chapter 4) provides an overview of the raw data to give an idea of what
the different signals look like in a variety of subjects and during a variety of activities.
Chapter 5 reviews what signal processing is commonly done on such signals and what
algorithms and models I used to extract information from our data. The discussion
(Chapter 6) reviews the most important points covered in the document and provides
an outlook of what the future may hold for wearable physiological monitoring devices.
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Chapter 2
Background
2.1 Epidemiology of Cardiovascular Disease
According to the United States Centers for Disease Control (CDC), the top five causes
of death in the United States for 2007 were [1]:
1. Heart disease: 616,067/year
2. Cancer: 562,875/year
3. Stroke (cerebrovascular diseases): 135,952/year
4. Chronic lower respiratory diseases: 127,924/year
5. Accidents (unintentional injuries): 123,706/year
Heart disease and cancer are by far the leading causes of death. Of the two, heart
disease is more manageable because it is confined to one organ system, has been
studied for centuries, and many advances have been made in treatment [2]. Significant
effort led to these new treatment efforts over the past several decades, including
statins, antihypertensive agents, thrombolytic agents, agents for heart failure and
antiarrhythmic agents [3]. Such treatments, coupled with improved prevention, are
likely the reason for a steady decrease in the number of yearly deaths attributed to
cardiovascular disease, as seen in Figure 2-1 [4]. It is also likely that such aggressive
Leading causes of death for all ages
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Heart disease
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Figure 2-1: Top causes of death in the US for 2007 as reported by the CDC. Note the
log scale of the y-axis. Taken from [1].
treatments have led to the explosion in health care costs seen in Figure 2-2 [5]. Costly
testing, hospitalization and treatments may be some of the reasons for the steady
increase. For example, the CDC estimates that 6 million hospitalizations a year are
due to cardiovascular diseases [6]. It is estimated that the total cost of heart disease
has a price tag of $475 billion annually [7]. Though outcomes for heart disease are
improving, the increasing costs are not sustainable, particularly given the aging U.S.
demographics, and new solutions for diagnosing and managing these diseases must be
found. Exercise, a healthy diet and not smoking are very low-cost solutions, and have
been explored for decades [8]. Though such changes in lifestyle are important pieces
of the solution, the data presented demonstrates the need for additional solutions.
It is also significant that the 3rd and 4th biggest killers are cerebrovascular disease
and chronic lung disease. Cost of treatment of chronic lung disorders and hyperten-
sion follows just after heart conditions, cancer, trauma, and mental illness [9]. New
solutions should also investigate ways to address these related problems.
Solutions need to reduce costs, must not impose a new burden on the time of
the health care providers, must reach a broader population, and continue to improve
patient outcomes. Cheaper technology, more efficient use of resources, and reduced
Personal health care expenditures,
800.. by source of funds
700- Private health insurance
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=500- 500- Medicare
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E
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100- MedIcaid (state)
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Figure 2-2: Health care cost from 1998 to 2008. Note the doubling of private health
insurance costs. Taken from [1].
hospitalizations will all reduce costs. For example, it has been estimated that 1 in
10 hospitalizations is not necessary [10]. One challenge with monitoring cardiovas-
cular and pulmonary conditions outside of a care setting, though, is that they often
progress slowly and cannot be discovered early with a static view. Long-term wearable
monitors pose one possible solution to reducing the cost of diagnosis and late-stage
treatment by preventing people from having to come to the hospital while offering
the hope of improved disease management and outcomes.
2.2 Cardiovascular Anatomy and Physiology
Anatomy is the study of the structure of living things. It involves studying static
structures, including the examination of cadavers for human anatomy. Physiology is
the study of the function of the body. Physiology is concerned with the behavior of
specific parts of the body over time. Some quantities, such as internal temperature
or blood pressure, are meaningful in as a single value taken at one time, but the vast
majority of information is contained in the change of interacting variables over time.
Physiology involves the identification of variables, the quantification of such variables,
the recording of the values of those variables, and the relating of those variables to
Superior
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Figure 2-3: Anatomy of the human heart. Taken from [11].
each other in a time dependent fashion to understand the mechanisms giving rise to
the relationships among variables.
2.2.1 Cardiovascular Anatomy
Regions
The structure of the heart is shown in Figure 2-3 for reference. The heart is divided
into four chambers, the two atria and the two ventricles. The atria receive blood from
the periphery and propel it into the ventricles. The ventricles create the pressure for
the blood to flow out of the heart. The heart is divided into the right and left heart,
which pump blood to the lungs and the systemic circulation, respectively.
Valves
Just as there are four chambers in the heart, there are also four valves in the heart.
The two atrioventricular (AV) valves open when the ventricular pressures drop be-
low their respective atrial pressures so the atria can empty into the ventricles. The
pulmonary and aortic valves prevent blood that has left the heart from leaking back
into the ventricles. They open when the ventricular pressures rise above that of the
pulmonary artery and aorta, respectively, during contraction of the heart muscle.
Blood circulation
Blood enters the right atrium via the venae cavae and the coronary sinuses. From
there it passes through the right AV (tricuspid) valve to the right ventricle. During
ventricular contraction, it leaves the right ventricle through the open pulmonary
valve and enters the pulmonary circulation via the pulmonary artery. In the lungs,
the blood is oxygenated in the pulmonary capillaries. The oxygenated blood arrives
back at the heart through the pulmonary vein, which empties into the left atrium.
From the left atrium, blood passes through the left AV (bicuspid) valve and into the
left ventricle. The left ventricle expels the blood from the heart through the aortic
valve into the aorta and on to the coronary and systemic vasculature.
Muscle force
The myocardium, or muscle of the heart, is an involuntary muscle that contracts
approximately once per second in the adult. The muscle wall in the atria is thinner
than in the ventricles and only provide a small amount of pressure. Because the atria
are situated above the ventricles, gravity and pressure differences provide most of the
force needed to move blood into the ventricles, but the atria do contract to make sure
the ventricles are filled. The right ventricular wall is smaller than the left as it only
creates around 15 mmHg of pressure to send blood to the lungs. The left ventricle
has much thicker walls to create the pressure (on the order of 100 mmHg) to send
blood to the peripheral circulation.
Electrical path
The heart is an electromechanical coupling device, converting electrical energy into
mechanical work. The sinoatrial (SA) node is located at the junction of the right
atrium and the superior vena cava, and is the "pacemaker" of the heart. Normally,
electrical impulses originate at the SA node and propagate in a highly organized
fashion through the heart wall, or myocardium, to ensure synchronized mechanical
Electrical System of the Heart
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Figure 2-4: The cardiac conduction system is shown in green with the white arrows
indicating the direction of travel of the electrical impulses. Taken from [12].
contraction. Conduction fibers travel throughout the walls of the atria and connect
at the AV node. All electrical signals must go through this node, which is the only
electrical coupling between the atria and the ventricles. The conduction fibers then
travel down the septum (bundle of His - left and right bundle branches) between the
ventricles and up the opposite sides of the ventricles, where they branch into the fine
Perkinje fibers. Each impulse from the SA node leads to an atrial contraction, slows
through the AV node, and then quickly depolarizes the ventricles to result in a coor-
dinated contraction. See Figure 2-4 where the conduction system is shown in green.
Following cardiac depolarization in each chamber, the chamber then repolarizes.
Excitation-contraction coupling
A sequence of events ensues at the cellular level to convert the electrical activation
into mechanical force. The action potential arrives at the cell membrane and spreads
to the interior, which increases the calcium conductance of special membrane channels
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Figure 2-5: Ion transport in cardiomyoctyes resulting in tension. The sequence of
events that leads to tension is on the left with a diagram of the pathway on the right.
Taken from [13].
and leads to an inward current of calcium ions. The subsequent increase in intracel-
lular calcium concentration triggers the release of more calcium ions stored in the
sarcoplasmic reticulum. The cytosolic calcium binds to troponin C which allows for
the proteins actin and myosin to interact. According to the sliding filament theory,
interdigitated protein filaments move relative to each other with one end of each fil-
ament anchored in place. Thick filaments, comprised of myosin, and thin filaments,
comprised mostly of actin, slide along each other in opposite directions to produce
tension. Calcium is not the only ion involved in the process, but the primary con-
tributor. Figure 2-5 shows the detailed pathway that results in force generation. The
balance of ions is returned to normal levels during repolarization.
2.2.2 Cardiovascular Physiology
Central component
The primary purpose of the cardiovascular system is to circulate blood to deliver nu-
trients and remove waste products. Cardiovascular physiology is therefore concerned
with how the heart and circulation accomplish these goals. The heart operates by
contracting its muscle to create pressure in the ventricles of the heart. Pressurized
blood then flows to regions of lower pressure, particularly the systemic circulation.
The entire circulatory system therefore follows a pressure gradient from its peak pres-
sure in the left ventricle, to lower pressure in the aorta to lower pressure in the arteries
to the arterioles and so on, until the lowest pressure is achieved in the right atrium
for a supine subject. The heart creates pressure by contracting, and then relaxes
to prepare for the next contraction. These phases are termed systole and diastole,
which together comprise one cardiac cycle or heart beat. One of the quantities of
prime interest in this context is cardiac output, defined as the average volume of
blood leaving the heart per unit time, typically calculated as liters/min. The cardiac
output is determined by how often the heart can cycle (heart rate) and how much
blood it can eject during each systole (stroke volume). The temporal profiles of key
variables during the cardiac cycle are shown in Figure 2-6.
During diastole, the AV valves are open and blood empties from the atria to the
ventricles. When the SA node fires, the atria contract to maximize the volume of
blood in the ventricles. Towards the end of atrial contraction, the ventricles start to
contract, closing the AV valves and opening the pulmonary and aortic valves when
the ventricular pressures exceed that of the atria. At the end of systole, the ventricles
relax. The pulmonary and aortic valves close and the ventricles further relax until the
ventricular pressures are lower than that in the atria, at which point the AV valves
open and blood begins to flow from the atria to the ventricles once more. Figure 2-7
shows the heart during diastole and systole with valve states and blood flow path.
The ventricular pressure needs to be lower than the filling pressure for blood to fill
the ventricle, but also greater than the aortic pressure to leave the left ventricle, so
it ranges from 0 to around 120 mmHg.
Peripheral component
The relationship describing average blood flow through the peripheral circulation is
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Figure 2-6: The temporal profiles of the cardiac cycle. LVP - left ventricular pressure,
AP - aortic pressure, LAP - left atrial pressure, LV - left ventricle, LVEDV - left
ventricular end diastolic volume, LVESV - left ventricular end systolic volume. Taken
from [14].
where AP is the drop in pressure from the arterial to the venous side, and R is the
lumped (aggregate) resistance of the peripheral circulation. Equation 2.1 can also
be applied to a local vascular segment. In this case, AP is the driving (perfusion)
pressure of that vascular bed and R is the local vascular resistance.
Not only do the various tissues of the body require different amounts of blood,
they have time-varying blood requirements. During some activities, such as exercise,
the proportions of blood going to various organs will need to change as compared to
other activities. The cardiovascular system is beautifully designed to decouple the
source from the periphery under normal physiologic conditions. Thus, local metabolic
demands of tissue govern the local flow of blood by modulating the resistance in
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Figure 2-7: Diagram of the heart during diastole and systole. The red arrows represent
the flow of blood and the green lines represent the valves in the heart. Taken from
[14].
Equation 2.1. Figure 2-8 shows a schematic of the circulatory system under resting
conditions, with approximate percentages of blood divided amongst the various organ
systems. The resistance of blood vessels is modulated by changing the diameter of
the vessel in a nonlinear fashion as given by the Poiseuille equation:
R = L (2.2)
wr 4
where R is the resistance of the vessel, y is the viscosity of the fluid, L is the length
of the vessel and r is the radius of the vessel. The Poiseuille equation only applies to
laminar flow. Blood flow in the smaller vessels is generally laminar, but cannot be
assumed to be at all locations [15]. The factors determining whether flow is laminar
or not include the velocity of the fluid, the length of the vessel, the radius of the
vessel, and the viscosity, which in blood is strongly dependent on the red blood cells.
Although not strictly applicable to the cardiovascular (CV) system, the Poiseuille
equation is still instructive as it shows the strong dependence of resistance on the
vessel radius.
An additional property of the vasculature is the incremental compliance of the
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Figure 2-8: Peripheral circulation diagram showing the approximate
diac output to each region of the body. Taken from 116].
percent of car-
vessel, which is defined as the change in volume for a given change in pressure:
AV
AP
(2.3)
Compliance, the ability to store potential energy, is analogous to capacitance in an
electrical circuit. The product of the resistance and the compliance is therefore a time
constant for the energy stored in the elastic vessels of the circulatory system. The
vast majority of the compliance can be found in the arteries and the vast majority of
the resistance is in the arterioles.
2.3 Cardiovascular Control
The physiology described up to this point assumes an open loop system where the
body is not receiving feedback to control the desired physiologic variables. In reality,
the body does tightly control its internal environment, which is commonly referred
Set Point
Figure 2-9: A basic control feedback block diagram. The setpoint for a given variable
is the input on the left. The output tracks the setpoint as closely as possible given
the constraints of the system.
to as homeostasis. Numerous feedback control loops are used to maintain homeosta-
sis. Such feedback loops include the sensors of the variables to control, the control
logic, and effector mechanisms to change the variables. The system is even more
complicated because external demands on the body require changing the setpoints.
2.3.1 Sensors
The primary variable of interest in the cardiovascular system is blood pressure. There
are several ways this is measured in the body, with the predominent way being the
baroreceptors [16]. In the wall of the carotid sinus and the aortic arch are stretch
receptors, which indirectly sense pressure. When the pressure increases in the vessels
and the walls are stretched, action potentials are fired in afferent nerves that connect
with the brain stem. The carotid baroreceptors sense both increases and decreases
in pressure, whereas those in the aortic arch primarily respond to increases. The
baroreceptors are sensitive to the absolute value of pressure, but appear to be much
more sensitive to changes in pressure and the rate of change of pressure.
Longer-term changes in blood pressure are sensed by the kidneys which are able
to modulate a hormone response. Other sensors include the peripheral and central
chemoreceptors, which are chemical sensors that sample the concentration of 02 and
CO 2. In the periphery they are located in the carotid bodies and the aortic bod-
ies, where there is high blood flow. They primarily respond to decreases in partial
Output
pressures of 02 and increases in partial pressures of CO 2. In the brain, where the
chemoreceptors are very sensitive, CO 2 is sensed by a change in pH.
2.3.2 Effectors
Sympathetic
The sympathetic system supports an enhanced response to stress, and counteracts
the effects of the parasympathetic system, which works to keep the body at rest. In
the sympathetic system, preganglionic neurons release acetylcholine, which stimulates
postganglionic neurons to release epinephrine and norepinephrine, which in turn acti-
vate the effector mechanisms. These mechanisms include: an increased firing rate of
the SA node, leading to increased heart rate; increased concentration of calcium ions
in myocytes, leading to increased cardiac contractility; and increased smooth muscle
contraction in the veins and arterioles, leading to increased venous tone and greater
peripheral resistance. Other effects include dilated pupils, dilated bronchioles, and
inhibited digestion.
In the cardiovascular system, the effectors above result in increased blood pressure
and cardiac output. In the periphery, the increased resistance in the majority of
arterioles results in a lower relative resistance in areas with higher metabolic demands,
such as skeletal muscle or the brain, which leads to a proportionally greater blood
flow to those areas. The sympathetic system has also been shown to contribute to a
host of other reactions helping the body cope during exercise [17].
Parasympathetic
If the sympathetic system is thought of as the gas pedal of a car used to ramp
up cardiac output, then it is necessary to have brakes when stopping sympathetic
outflow is not sufficient. The parasympathetic system provides this action. In the
parasympathetic system, acetylcholine is the primary neurotransmitter, interacting
with muscarinic and nicotinic receptors to produce the effector mechanisms. The
parasympathetic system primarily acts through stimulation from the vagus nerve,
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Figure 2-10: Control feedback block diagram for the cardiovascular system. The
control logic is housed in the brain stem where afferent fibers carry information from
the sensors and efferent fibers carry information to the effector organs. Some effector
mechanisms are shown in the green box and sensors in the blue box. Sample variables
to control are blood pressure or cardiac output in the cardiovascular system and
respiration rate in the cardiopulmonary system.
which has the opposite effect of what is described in the sympathetic section. Effects
of the parasympathetic system include decreased heart rate and increased digestion.
Balance
In the past two decades, great emphasis has been spent trying to understand the
autonomic control of the cardiovascular system. The prevailing hypothesis is that an
imbalance of the sympathetic and parasympathetic responses leads to a greater risk
of arrhythmias and sudden cardiac death, as demonstrated by direct recordings of
vagal and sympathetic fibers [18]. It appears that vagal activation has an antifibrilla-
tory effect, which has strong implications for risk assessment and implanting internal
cardioverter defibrillators (ICDs) [19]. It has also been hypothesized that the degree
of each response at rest can be used as an indication of cardiac health [20]. See Figure
2-10 for a simple block diagram of the feedback control of the cardiovascular system.
2.3.3 Hormonal Feedback
Nerves provide rapid feedback and modulate the cardiovascular system on short time
scales. On longer time scales, chemical modulation can be used to regulate blood
pressure. The Renin-Angiotensin II-Aldosterone System (RAAS) senses decreases
in renal perfusion pressure, which then leads to the release of angiotensis II, which
results in increased thirst, increased peripheral resistance and sodium reabsorption,
all of which help increase the arterial blood pressure.
2.3.4 Local Control
In addition to being controlled by the sympathetic system, the periphery can also be
modulated on a local level. The prevailing hypothesis is that local metabolic demands
control the resistance in local vessels. (Another hypothesis is that when smooth
muscle is stretched, it contracts. This can explain how flow can remain constant
with fluctuating blood pressure, but cannot explain active or reactive hyperemia.)
Each organ reacts differently, but an increased local metabolic demand will translate
into a decrease in resistance by decreasing smooth muscle tone via the nitrous oxide
pathway, in order to increase blood flow.
2.3.5 Cardiopulmonary Coupling
This is an active area of research. It appears that there are incidental couplings that
serve no apparent purpose, and intentional couplings that work together to ensure
the delivery of oxygen and removal of carbon dioxide in the correct amounts to and
from the body. It is possible that the mechanical couplings are not functional, such
as sinus arrythmia, which is the change in heart rate due to the change in thoracic
pressure during breathing. On the other hand, there are working hypotheses that
suggest the same neural source controls both systems to some degree, and that there
is an ANS coupling.
Measurements of cardiac and respiratory functioning are connected by the fact
that the impedance of the chest changes during respiration, which results in the
modulation of the ECG signal.
2.4 Exercise Physiology
Some physiological variables are useful to analyze during a state of rest, but some
information is much more revealing in the presence of a physiological stimulus. The
study of the heart in a clinical setting has been extensive, especially the study of
changes noted in a variety of illnesses. The vast majority of this information has
been garnered from hospitalized patients, often in the supine position under tightly
controlled circumstances. Much information can be obtained by testing how the car-
diovascular system equilibrates at rest, however, further information can be obtained
by probing the system during activity.
The most common clinical stress test is the exercise test. During such a test,
the patient is monitored with various ECG leads while increasing the level of exer-
cise. Subtle changes in the rate or morphology of the ECG in response to exercise
allow cardiologists to diagnose a variety of disease conditions. Other tests have been
validated, but are mostly used in research settings.
2.4.1 Physiological Response
It is clear that the increased metabolic demand of exercising skeletal muscle will
require increased blood flow. The increased demands result in new setpoints in the
control system, but the effectors and sensors remain the same. The literature explains
some aspects of how this happens, but there is ample room for exploration. One
challenge is that precise testing is hard to execute in exercise conditions, resulting in
limited data.
Heart
The primary purpose of the heart is to pump blood through the body. The most
valuable information in characterizing the performance of the heart is how much
volume of blood is being pumped per unit time, which is known as cardiac output
(CO) and is often reported in units of liters/min. The basic formula for calculating
cardiac output is:
CO = HR * SV (2.4)
where stroke volume (SV) is the volume of blood ejected from the heart during systole.
The heart rate (HR) is largely governed by the sympathetic and parasympathetic
branches of the nervous system which innervate the SA node in the heart. Their
firing rate is determined by control logic in the brain, which uses several sensors in
the body such as blood pressure and metabolic demand.
The stroke volume by definition is the difference between the end diastolic ven-
tricular volume (EDVV) and the end systolic ventricular volume (ESVV). The ESVV
is a function of the contractility of the ventricle, determined by the sympathetic tone
and health of the myocardium, as well as the afterload, which is the arterial blood
pressure that the heart has to pump against. The EDVV is a function of the com-
pliance of the ventricle (which should not change significantly on short time scales)
and the filling pressure, which relates directly to the total distending blood volume
(TDBV) or the volume of stressed blood in circulation. TDBV is a function of total
blood volume and venous tone.
To summarize, CO is the value that is of central interest in characterizing the
heart, because it most directly relates the flow of oxygen and nutrients to metabol-
ically active tissue. Several variables can be defined that contribute to CO, such as
heart rate, filling pressure, contractility, and afterload.
The most apparent change during exercise is the increase in heart rate. Increased
heart rate accounts for most of the increase in cardiac output, and has been shown to
increase linearly with workload and oxygen uptake [21]. Stroke volume also increases,
but only by 50% to 60% of normal resting stroke volume (whereas heart rate more
than doubles). Research continues to examine how CO, HR and SV change during
exercise, and how they depend on a variety of other variables such as age, gender,
activity levels and smoking habits. For example, it has been demonstrated that heart
rate during exercise decreases with age, but can be compensated by an increased
stroke volume in healthy subjects [221.
As mentioned previously, stroke volume is modulated by filling pressure, con-
tractility of the ventricles, and mean arterial pressure. Filling pressure is in part
determined by intrathoracic pressure, which changes during the breath cycle, but is
mostly modulated by changing blood volume and the venous tone. Blood volume
changes as fluids are lost or consumed over a scale of minutes to hours. A change
in venous tone results in a change of the total stressed blood volume in the circula-
tion. An increased filling pressure will result in larger EDVV, thus increasing stroke
volume.
Contractility can change by increasing or decreasing the tension generated by
the myocardium. In conjunction with the afterload, contractility determines the
end systolic volume. Although the cardiac output can increase by as much as 5-fold
during activity, the mean ABP only increases slightly because of the large concomitant
decrease in peripheral resistance. Measuring stroke volume in an exercising subject
is a difficult task, and results are varied [23].
Another quantity that changes over longer periods of time is ventricular compli-
ance. For example, as a result of hypertension, the myocardium may hypertrophy,
resulting in a thickened left ventricular wall. Hypertrophy will decrease the compli-
ance and therefore the EDVV, but the time scale is years.
Periphery
The entire peripheral system adjusts to accommodate exercise. Many organ systems
such as the GI tract are less important during exercise, and blood flow to the gut is
accordingly reduced during exercise. The skeletal and cardiac muscle on the other
hand experience a large increase in blood flow. As mentioned previously, this is mod-
ulated by the local control of arteriolar diameter, and is the only acute response to
exercise readily observed in the periphery. Long-term changes such as increased capil-
lary density can have a significant effect. Damage to the cardiovascular system could
manifest itself during exercise, but the mechanisms are diverse and not specific in
their manifestations. It is therefore not likely possible to diagnose specific peripheral
diseases with such data, but the data can still be useful in evaluating the vasculature
response as a whole.
Cardiac output function curves
A convenient way of understanding what influences cardiac output, which is equal to
venous return, is using cardiac and vascular function curves. The cardiac function
curve shows how much blood the heart can pump and the vascular function curve
shows how much blood can be returned through the vasculature to the heart. Both
are plotted as a function of right atrial pressure. The actual cardiac output is the
intersection of the two curves as seen in Figure 2-11. Each curve can change, resulting
in a new cardiac output. When the cardiac contractility increases, a positive inotropic
effect, the slope of the cardiac function increases and moves the intersection point
higher. A change in the blood volume shifts the vascular function curve up or down,
again resulting in a different intersection. Changes to TPR change both the cardiac
function, as a result of a changed afterload, and the vascular function, as a result of
changed flow to the veins. Figure 2-12 shows examples of how changes in the CV
system result in CO changes.
2.5 Physiological Exercise Testing
Two significant advantages of exercise testing are the low cost and the ability to
probe the system with external stimuli. There are two general goals with such tests,
diagnostics and prognostics. For diagnostic purposes, several characteristics have been
associated with certain conditions. For example, changes in the ST segment of the
ECG are related to ischemia, which can be connected to coronary artery disease. The
prognostic value of exercise tests is more subtle and less commonly used. Certain
effects, like a delayed heart rate recovery, have been associated with a higher risk
of mortality. While this may influence treatment, it does not necessarily give you
information about what is wrong. It can also be used to evaluate damage following
an event such as a myocardial infarction. A few conditions that can be evaluated
with physiological testing (exercise and otherwise) include congestive heart failure,
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Figure 2-11: The cardiac and vascular function curves provide insight into what
determines cardiac output. The cardiac function curve is an indication of how fast
and intensely the heart is beating. The other component affecting cardiac output is
the amount of blood returned to the heart, or the venous return, which depends on
the total distended blood volume. Taken from [16].
arrhythmias, respiratory disorders and sleep apnea.
2.5.1 ECG
The electrocardiogram (ECG or EKG) is a measurement of the voltages produced by
the heart as measured at the surface of the body. Willem Einthoven demonstrated the
first practical ECG measurement in 1903 and received the Nobel Prize in Medicine
for it in 1927.
How it works
On a cellular level, each cell membrane has a transmembrane voltage based on the
concentration of ions inside and outside of the cell, the ions of interest being sodium,
potassium, calcium and to a smaller extent, chlorine. The cardiac muscle cells de-
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Figure 2-12: The above plots show what effects certain changes will have on the
cardiac function and vascular function curves, which will change the cardiac output.
Taken from [16}.
polarize in the same manner as skeletal muscle, in that sodium channels open and
sodium ions rush into the cell. This influx raises the resting membrane potential from
around -85 mV to +40 mV. At the same time there are other slower ion channels
whose conductance changes. The balance of the various ion channel conductances
results in the shape of the action potential, which differs slightly depending on the
location within the heart. Each action potential has five phases: a fast depolarization
(0), a quick small repolarization (1), a plateau as the ion flows going in and out are
equal (2), a repolarization tail (3), and a period of rest without activity (4). The
phases are seen in Figure 2-13 with the approximate flux of ions.
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Figure 2-13: A cardiac action potential is shown with the five phases labeled and the
associated exchange of ions across the cell membrane. Taken from [24].
The sum of all of these action potentials (time shifted according to where in the
cardiac cycle they appear) is what the ECG is capturing as seen in Figure 2-14. In
short, the ECG is the aggregate surface potential of all the depolarizations and repo-
larizations of all cells in the heart as they occur over the cardiac cycle. The features of
the ECG occurring at specific times will therefore provide information about specific
locations within the heart. Thus time points on the ECG encode for spatial regions
in the heart. Boundaries are not always clearly defined because multiple areas may
undergo depolarization or repolarization at the same time, resulting in overlap.
The utility of the ECG is enormous because the measurement reveals a great deal,
yet is taken on the surface of the skin rather than needing direct access to the heart.
The downside is that the electrical signal must travel through the tissue to the surface
of the body, which attenuates and shapes the signal. The electrical propagation can
be modeled using a current source inside a conducting medium, which for simplicity
is modeled as a sphere of homogenous conductivity. The surface potential at a given
Timo is
Figure 2-14: Action potentials at different locations in the heart and how they com-
bine over the beat to result in the standard surface potential, which is the ECG. It
can be seen that the electrical impulse travel slowly through the SA and AV nodes,
distorting the shape of the template shown in Figure 2-13. Taken from [25].
location is given by the equation
<b(R,0) 3M coso (2.5)4ro-R2
where MO is the current source, o is the conductance of the torso, R is the distance
from the source and 0 is the angle between the heart vector (which is the general di-
rection of propagation of the action potential through the heart) and the lead vector
(which is the line between the source and the observation point) [26]. The ECG mea-
surement is the difference in potential between two such observation points. Equation
2.5 shows the importance of understanding what the ECG is when placing leads as
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Figure 2-15: The basic ECG shape showing the P-wave, corresponding to depolar-
ization of the atria; the QRS-complex, corresponding to the depolarization of the
venctricles; and the T-wave, corresponding to the repolarization of the ventricles.
Taken from [27].
the measured signal will depend strongly on placement.
Interpretation
Interpreting ECG waveforms involves examining the relative start time and shape
of the various components: P-wave, QRS-complex and T-wave. These features are
highlighted in Figure 2-15. Encoded in the shape is the magnitude and duration of
each feature, which provides information about the conduction system. The pres-
ence of one feature without another may represent a block in conduction somewhere.
A broadened feature may indicate slow conduction, such as when the signal travels
through the normal myocardium in the ventricles instead of the Purkinje system.
Sometimes the regular features might disappear altogether, as in ventricular fibrilla-
tion, when the normal conduction system is bypassed.
Clinical Relevance
The greatest clinical impact the ECG has had is detecting arrhythmias and extracting
heart rate. There is a wide variety of arrhythmias that can be diagnosed by the trained
eye looking at an ECG. Typically they can be characterized by location (the atria,
the AV node and the ventricles), rate (bradycardia and tachycardia) and mechanism
(ectopic). Premature contractions, tachycardia, flutter and fibrillation can take place
in all chambers.
Some arrhythmias pose no risk to the patient, while others merit close watching
even though nothing can immediately be done. Some arrhythmias, such as atrial fib-
rillation or serious tachycardias, can be treated with drugs or ablation. A propensity
for a life-threatening arrhythmia such as ventricular fibrillation warrants implanting
an ICD. A significant amount of effort has been invested in automatic detection of
arrhythmias. For a more detailed treatment of specific arrhythmias see [26].
2.5.2 Respiration
There are various measurements of interest in the field of respiratory physiology.
These measurements center around the volume of gas exchanged as well as the com-
position of the gas exhaled (composition of inspired gas changes relatively little and
is not changed by physiology). The values can be examined per sample, per breath,
or averaged. From waveform data, several key features can be extracted, such as tidal
volume and respiration rate. Specific standard tests are used to extract other quan-
tities, such as performing a complete inhalation/exhalation or forced exhaled vital
capacity in one second (FEV1 ).
The gas composition can be studied to analyze gas exchange at the level of the
alveoli, but this should not change on a time scale of minutes to hours. Consequently
percent composition of C02 can be used as an estimate of total volume expired.
Gas volume transfer is inherently a variable signal. Unlike the cardiovascular
system which is regulated by the autonomic nervous system, the respiratory system
can be overridden and controlled by the user; it does not necessarily have to follow
a periodic pattern as the electrical activity of the heart. It is therefore much more
difficult to distinguish between normal and disturbed breathing. Respiration rate is
derived from the volume exchange data and is therefore also an unsteady signal.
The most direct measurement of respiration is spirometry, which measures lung
function using a tube that the subject is required to blow on during exhalation. The
volume of the exhaled air can be measured in this way, or its composition can be
sampled. One challenge of spirometry is the cumbersome equipment, which is un-
comfortable and in some situations/environments impractical to use. Other methods
are available, such as measuring the expansion of the chest and abdominal cavities.
This option is attractive because of the ease of implementation. It is possible to cal-
ibrate such a measurement for accurate for volume, or simply possible to get relative
values from which respiration rate can be extracted.
2.5.3 Arterial Blood Pressure
Blood pressure, and specifically arterial blood pressure, is a key vital sign. The
heart acts as a pressure source, and there is a gradient of pressure throughout the
vasculature, from the aorta to the vena cava. Mean pressure is fairly constant in the
arteries, drops a little across the arterioles, and then drops significantly across the
capillaries, until it is close to atmospheric pressure in the veins. The value of greatest
interest is the arterial blood pressure (ABP). The systolic and diastolic values of
the arterial blood pressure are very easily determined using a pressure cuff and a
stethoscope. Disadvantages of this technique are that it is slow (10-20 seconds per
measurement) and only yields two values, the systolic and the diastolic pressures.
The most accurate way to measure ABP is by placing a pressure transducer di-
rectly in the radial or femoral artery as is done quite routinely in critical care settings.
This method will give a continuous waveform with time resolution dependent on the
sampling rate. The data is considered very reliable and can be high resolution. The
drawbacks of catheterization are pain, the need for trained personnel and restriction
of movement.
The one continuous-time noninvasive option that is available is a mix between the
preceding two. A small cuff is placed on the finger and its pressure is dynamically
controlled pneumatically to maintain the volume of the cuff, so its pressure matches
the pressure in the artery [28]. This option is not considered as accurate as a catheter,
but is much easier to implement and can be portable.
2.5.4 Pulse Plethysmograph
Pulse plethysmography is a simple and elegant technology used ubiquitously in hos-
pital settings. The sensor has two possible modes. The first uses two wavelengths of
light to detect two different states of hemoglobin. When hemoglobin is completely
bound to four oxygen molecules, one wavelength is more strongly absorbed. The
other is absorbed when the hemoglobin is not bound to oxygen. The ratio of light
absorbance through the finger at these two wavelengths provides an estimate of what
percent of the possible amount of oxygen is present in the blood. This is referred to
as pulse oximeter mode or spot oxygen saturation (SpO 2 )-
The second mode uses the fact the total incident light absorbed is a function of the
volume of blood in the finger because blood strongly absorbs certain wavelengths. The
waveform could then be used as an approximation for the ABP, but is not calibrated,
as it depends on the compliance of the artery. This information can be used as an
easy way to calculate heart rate.
2.5.5 Accelerometry
Accelerometers have made their way into everyone's pocket because they are inex-
pensive and can be placed in phones. Consequently they are innexpensive and easy
to obtain. With an accelerometer, gravity must be taken into account; if one axis
is directly facing away from the earth, that axis will read 1 G of acceleration. At a
different angle there will be a trigonometric relationship with the angle between the
accelerometer axis and gravity.
2.5.6 Stress Test Equipment
Other equipment commonly used for physiological testing is aimed at inducing a phys-
iological response. This could be passive, such as a tilt table test, but more commonly
it is an exercise test. A distinction should be made between isometric exercise and
dynamic exercise. Isometric exercise involves minimal external movement, which in-
creases the load on the left ventricle. Dynamic exercise is rhythmic muscular activity
involving external movement. The motion in dynamic exercise is easier to translate
into an estimated work load and is therefore preferred for testing. The disadvantage
is that motion often is a source of noise in instrumentation.
The preferred methods of exercise in a controlled setting are cycling on a station-
ary bicycle or walking/running on a treadmill. The treadmill involves more muscle
groups and subjects often perform slightly more work. It is also very simple to keep
the exercise load constant by maintaining a constant speed on the treadmill. On a
bicycle, pedaling speed is a large factor of workload and is controlled by the individ-
ual, thus varying over time. Another disadvantage of the bicycle is that individuals
may be using upper body muscles, which would be undetected isometric exercise.
The advantages of cycling include the individual's upper body remaining still and the
possibility of using a bicycle in the supine position for very unhealthy people. See
[21] for more detailed information.
2.5.7 Protocols
Exercise protocols for cardiovascular testing were introduced as early as the 1950s
for testing Air Force personnel [29]. Treadmill protocols are centered on speed and
percent grade. Bicycle protocols can be estimated to achieve approximately the same
level of energy expenditure. Some protocols fix the speed and only adjust the grade,
while other protocols adjust both. The protocol introduced by Bruce in 1971 has
remained the most popular, as indicated by surveys conducted in 1980 and 2000
[30, 31, 32]. Though these are still the most commonly used, it has recently been
shown that smaller, more equal increments in workload are best [33]. Others have
concluded that the protocol should be tailored to the individual and the disease, but
general guidelines recommend an 8-12 minute test duration [21].
Another approach is to ignore protocols and attempt to continuously ramp the
workload to reach maximum oxygen uptake over a 10-minute time period. This
approach is done by estimating the maximum, allowing the subject to warm up for one
minute at a comfortable speed and then adjusting the speed and grade continuously
until the maximum oxygen uptake (V0 2 max) is reach at the 10 minute mark.
It is also often useful to use the subject's perceived exertion. A Borg scale is from
6 to 20 and then converts to a 1 to 10 scale [34, 35]. This has strong limitations, but
can be very convenient.
One recommendation for the postexercise period is to have subjects stand mo-
tionless for a few seconds after stopping exercise and then have the patient lie down.
It has been shown that this can enhance ST-segment abnormalities instead of a cool
down period [36].
2.5.8 Hypothesis
In our experiments we look at heart rate, mean blood pressure and pulse pressure. We
also examine estimates of cardiac output and total peripheral resistance. In response
to exercise, we would expect an exponential increase in cardiac output asymptotically
approaching a steady state. Moderate exercise would likely result in a small and quick
change, whereas a longer exercise period would result in an elevated and sustained
cardiac output. We would also expect the total peripheral resistance to decrease
according to the rate of increase of work load due to exercise.
Other maneuvers besides exercise also can provide valuable insight into cardio-
vascular control. For example the Valsalva maneuver is a common test that involves
bearing down and increasing intrathoracic pressure for a period and then releasing.
The increased pressure will decrease venous return and therefore reduce cardiac out-
put. We would expect to see blood pressure drop and then, if the baroreceptors are
working properly, an increase in heart rate to increase cardiac output. When pressure
is released, venous return increases and consequently the cardiac output as well. The
increased pressure is sensed and the heart rate should drop.
Another easy maneuver is standing up. There is a sudden upward movement of the
body against gravity, resulting in a decrease in venous return, causing blood pressure
to drop. The pressure drop should be sensed by the baroreceptors, and sympathetic
outflow should result in increased heart rate, cardiac output and TPR. The values
will equilibrate at a steady state value if the subject remains standing.
Chapter 3
Prototype Device and Data
Collection
We collected data from a prototype wearable cardiac monitor to evaluate perfor-
mance and explore applications. We also collected other physiological signals from
other wearable or potentially wearable devices to obtain a superset of physiological
data that could be probed. In this chapter I will describe the experimental device
in detail, as well as give an overview of the other equipment used. I will outline the
process for obtaining approval for conducting the experiments and describe the docu-
mentation required. The next section details the protocol followed. The chapter ends
by discussing some of the issues we faced with the prototype device and an outlook
for future devices.
3.1 Wearable Cardiac Monitor
The wearable cardiac monitor evaluated in this thesis (Figure 3-1) was designed as
a continuous, long-term, low-noise data recorder. The device is capable of recording
single-lead electrocardiographic and 3-axis motion information continuously for up to
two weeks.
It was designed in MIT's Microsystems Technology Laboratories (MTL) by Eric
Winokur in Prof. Charles Sodini's group. The printed circuit board (PCB) was
Figure 3-1: Wearable cardiac monitor. The device is made on flexible PCB with five
electrodes seen as the silver buttons. The large object on the top right is the battery
connected through the three wires. The large chip at the top soldered on four sides
is the TI MSP430 and the eight chips on the left are the flash memory.
fabricated by Advanced Circuits, Aurora, CO, and the electrical components were
then put in place at MTL.
The device was designed in the shape of an 'L' on flexible PCB to capture different
possible lead configurations. It is 10 cm long per side, with rounded corners, and
weighs only 28 g. It is a light and somewhat adaptable device that can be worn
directly on the chest using standard adhesion electrodes. It has five possible electrode
sites to which disposable electrodes can be snapped in place. The sticky side of the
electrode is then placed in direct contact with the skin, providing electrical contact
and mechanical stability.
Accelerometer
The accelerometer sensor is an off-the-shelf component (ADXL345, Analog Devices,
Cambridge, MA) which comes in a small (3 mm x 5 mm x 1 mm) plastic package
with 14 leads that are soldered to the PCB. The sensor itself is a polysilicon structure
suspended over the surface of a silicon wafer to provide resistance to force. A plate
in the fixed plane and one in the moving structure are the two sides of a differential
capacitor. A schematic of this concept and the SEM of a similar device are seen in
Figure 3-2. The device is capable of sensing +/- 8 G with 12-bit resolution, to give
4 mG's (1 G = 9.8 m/s 2 ) per least significant bit (4 mG/LSB). It is an ultra-low
current device, with current as low as 40 ptA at a typical supply voltage of 2.5 V.
Figure 3-2: The upper diagram illustrates the principle behind a micromachined
accelerometer in one axis. The fixed points are shown in green with black boxes
around them. During acceleration, the beam (which is not fixed) moves and the
fingers on the bottom move relative to each other, which movement can be measured
as a change in capacitance. In the lower figure is an SEM of an Analog Devices
ADXL202 showing the anchored points and the beam which is capable of moving.
The smallest movement detectable is approximately 2pm. Images taken from [37].
ECG
The ECG sensor consists of 5 button connectors, an analog front end with configurable
gain, and a ground drive circuit. The connectors were adapted from standard clinical
leads into which disposable snap electrodes directly connect. The ground drive circuit
provides 0 to 2.7 V bias voltage and AC common mode rejection. Three of the
five electrodes can be activated at one time, representing the ground, positive, and
negative terminals. The configuration of the three can be set before starting data
collection, but cannot be changed once it has started. See Figure 3-3 for a schematic
of the ECG portion of the device.
Figure 3-3: The schematic of the monitor shows the three electrodes on the left along
with the amplifier and common mode rejection. The MSP430 handles the analog-
to-digital conversion and any digital signal processing. The data is stored in flash
memory as seen on the right. Image taken from [38].
Power management
The power management circuit is simply a battery connected to off-the-shelf ana-
log regulator circuits (TPS78227, TPS62200 - Texas Instruments, Dallas, TX). The
circuit battery is a generic 4.2 V Lithium-Ion rechargeable battery. The power man-
agement maintains a constant 2.7 V for the rest of the components. The battery lasts
approximately one month in data collection mode.
Microcontroller
The microcontroller is an off-the-shelf MSP430 processor from Texas Instruments.
All of the analog-to-digital circuitry and a digital signal processing unit are on-board,
which allows for real-time processing of data. Signal processing was not integrated
into the work of this thesis, but real-time algorithms can be implemented based on
this thesis. The microcontroller communicates with all other circuitry on the PCB.
Memory/USB
The memory included on the device are five 64-megabit flash memory chips, for a
total of 320 megabits. A USB communication adaptor (FT232RL - FTDI, Hillsboro,
OR) connects to the microcontroller, allowing for configuration and transfer of data
from the memory.
Modes of operation
Two modes of operation are possible: configuration and data collection. Both modes
are accessed in software via the USB communication link. In configuration mode, a
set of parameters, including electrode selection and gain level, are sent to the device.
The data collection mode is started once the device is configured and only stops
when the user requests the data that has been recorded. After the data collection has
started, the device can be removed from the USB connector until the user wishes to
download the data collected. At that point, the device will again need to be connected
to a computer via the USB link. When connected to the communication link with
the device powered off, the battery recharges.
Placement
Once the device is configured and data collection has started, it is ready to be attached
to the subject. The electrodes are snapped onto the device and the plastic coating
on each electrode removed to expose the sticky contact. All five electrodes are then
snapped into place for greater mechanical stability, as opposed to only using electrodes
for the three active locations (ground, negative and positive). The device can then
be applied directly to the skin of the subject's chest. Preparation of the skin may be
desirable to enhance the signal quality, as described later. Care should be taken to
place the device properly on the first try, as removal will leave adhesive residue. The
electrodes should not be applied to the skin first, as alignment can then be difficult.
It is also more difficult to snap the electrodes into place since the human body will
absorb a lot of the force used trying to press the device onto them.
Orientation on the chest will depend on the application, but standard lead con-
figurations should be followed. The L-shape of the device allows for several different
orientations, but the following principles should be kept in mind when selecting the
orientation. The ground electrode provides a reference to be subtracted from the pos-
itive and negative terminals, and should be placed such that it will see approximately
the same interfering variations as the positive and negative terminals (common mode
rejection). One should keep in mind that the standard lead configurations have spe-
cific negative and positive terminal orientation. Getting the terminals backwards will
lead to an inverted signal with reference to the standard configuration.
Safety
Care was taken in the design to prevent possible hazards to the subject. The device
is flexible with rounded edges to prevent mechanical harm. The whole device is
covered in a waterproof polymer coating to electrically isolate the electronics from
the subject. Since the electrodes used have an impedance of approximately 100
kOhms, the maximum current that could possibly flow to the subject would be 27
pLA, which is two orders of magnitude lower than what a human can perceive. The
amount of power dissipated is 0.5 W/m 2 which is two orders of magnitude lower than
the thermal energy that a human radiates. In summary, this is an extremely safe
device for human subject use.
3.2 Equipment
3.2.1 Portapres
The arterial blood pressure (ABP) monitor used was a Portapres 152 (Finapres Med-
ical Systems, Amsterdam, NL). This device is a non-invasive, portable device that
estimates the continuous ABP waveform. A more accurate method to measure ABP
would be to place a catheter directly into a main artery that is connected to an
external strain gauge, but this is very invasive and by the standards of non-critical
care, would not be portable. Other cuff methods only give intermittent readings
( 1/min) and are cumbersome. The principle on which all Finapres systems are based
is measuring the pressure required to maintain real-time control of the size of an
artery [28, 39]. The finger is chosen as a convenient location to place a small cuff
with a bladder that is capable of changing pressure rapidly via a pneumatic servo
system. The cuff is also capable of measuring the relative blood volume in the finger
via infrared plethysmography. A control feedback loop keeps the size of the artery
constant, and the corresponding pressure of the cuff is the estimate of the pressure in
the artery. Many studies have compared the accuracy of the Finapres device to other
standard measurements such as intra-arterial recordings, with some varied results,
but a survey of that literature showed that the measurement errors are statistically
negligible [40, 41].
3.2.2 Pulse Plethysmograph
With a sensor placed on the finger, our Criticare 504-US (Criticare Systems Inc,
Waukesha, WI) can measure the relative blood volume which correlates to diame-
ter of the artery as well as oxygen saturation of the blood. The oxygen saturation
changes by very small amounts in healthy adults (even during extended periods of
breath-hold), and we therefore only recorded the pulse plethysmograph (PPG) wave-
form. Plethysmography is the measurement of the volume of an organ or tissue.
Photoplethysmography is the use of infrared light to measure the relative volume of
blood in arteries and arterioles by measuring the relative amount of light transmitted
through the finger.
3.2.3 Clinical ECG
Tracing the ECG setup from the skin to the recorder, disposable 3M Red Dot multi-
purpose monitoring electrodes were used (medexsupplly.com:3M-2560 - 3M, St Paul,
MN) with Welch Allyn ECG lead wires (medexsupply.com: WA-6200-05, Welch Allyn,
Skaneateles, NY). The lead wires were connected to a common line which fed directly
into the Criticare 504-US already mentioned, which has an input and output for ECG
to simultaneously monitor along with PPG. The output from the unit was a single
analog channel, and it appears that a bandpass filter is applied by the unit, with
passband approximately 0.01-40 Hz, though exact specifications of the processing of
the ECG signal are proprietary.
3.2.4 Respitrace
An Inductotrace System 10.9000 (Ambulatory Monitoring Inc., Ardsley, NY) was
used to record the relative respiration waveform from the abdomen and the chest.
The system consists of two elastic inductobands, an oscillator and a calibration unit.
The bands are fabric with elastic inside to make them stretch, and a wire running
through the fabric in a sinusoidal pattern. A cable clips onto the wires in the bands
and connects to the oscillator. The oscillator provides a high frequency (300 kHz)
AC current through the wire and measures voltage. If the inductance through the
wires changes due to stretching of the wires, that is reflected as a change in the
measured voltage. The calibration unit can be used with a spirometer to get an
absolute measurement, but since we were only interested in tracking respiration rate,
we did not calibrate our signal. Three channels can be collected: the abdomen, the
chest and the sum of the two.
3.2.5 Data Recorder
An eight channel digital data recorder was used (RD135T, TEAC America, Monte-
bello, CA) to convert the eight analog signals to digital, and then record them on
digital tapes (Sony DDS3 125P and Maxell R-120DM). While using all eight channels,
the default sampling rate is 12 kHz. Real-time visualization and control of the unit
was achieved on a data collection laptop.
3.2.6 Additional Equipment
Two devices that did not contribute to the data, but were instrumental in collecting
the data accurately were a time marker and signal generator. The time marker
includes a switch and a voltage source such that when the custom-made switch is
flipped, an analog pulse is generated. This signal can be used to mark events during
experiments to easily find them in the data later. The signal generator was used
to ensure data recording quality. With a 1 Hz input signal, it is possible to detect
any data corruptions (drops or insertions) that are not exactly 1 s, and measure the
length of such a corruption if it is less than 1 s.
3.3 COUHES Approval
The Committee On the Use of Humans as Experimental Subjects must give prior ap-
proval of any research at MIT involving the use of humans. This committee comprises
physicians, professors, students, technicians, religious and community personnel who
ensure that experiments comply with federal law and local ethics standards. The
committee is updated on the status of the project, and all changes must be approved
by the committee. A description of the three sections of the application is given
below. See appendix A.1 for the application corresponding to the study presented in
this thesis.
Basic Information
This section of the application focuses on the investigators involved in the study. The
PI must be named along with brief qualifications for conducting the study. All other
personnel involved must also be named and have completed the Human Subjects
Training. Additional information that needs to be included are any collaborations,
where the research will be conducted, and what the funding sources are.
Prof. George Verghese was the PI on the application, with several staff members
and students included as personnel. The experiments were completed at the MIT
Clinical Research Center and were funded by a gift from Texas Instruments.
Study information
The study section outlines the details of the study itself, starting with the purpose
of the study and then the details of the protocol. A subsection entitled Drugs and
Devices requires specific information on the use of drugs and experimental devices,
as well as the use of radiation and diets in the study.
Our experiments include an investigational medical device, and one of the attach-
ments provides a detailed description of the device, including safety considerations.
Human subjects
The third section is the longest and ensures that the study treats human subjects with
care. The number of subjects projected and the age range of the population must be
stated, along with any inclusion or exclusion criteria. If any vulnerable populations
such as prisoners, employees, students, children, cognitively impaired or non-English
speakers are included, justification must be made. Standard facts must be included
such as how subjects will be compensated, what the potential risks are, and what
the potential benefits are. There is a data handling section to ensure that privacy of
subjects is maintained and the investigators must comply with all HIPAA regulations.
Two very important sections are the adverse effects and informed consent. The former
details how the investigators will detect and respond to any harm that happens to
the study subjects. An informed consent document must be included exactly as it
will be given to subjects to ensure that they know the details of the study and make
a voluntary and informed decision about their participation.
We estimated 15 subjects ages 18-65 would be sufficient for a proof-of-concept
study. Exclusions were based on health history (particularly cardiovascular diseases,
surgeries or implants) and current health state (use of alcohol, pregnancy, sufficient
sleep). We allowed the use of students because they represent healthy young adults
who are ideal for this type of study. Our subjects were not compensated and were
offered no direct benefits. Possible risks were outlined in detail, even though they
were considered minimal. The types of data were delineated, along with how they
would be stored and secured. All our data was to be de-identified for processing.
Precautions were taken to ensure no harm to subjects, and a method of contacting
investigators after the study was put in place.
3.3.1 Accompanying Forms
In our application we also attached a description of the experimental device and the
informed consent form. Also included was a questionnaire given to each subject to
ascertain a healthy status at the time of the study.
3.3.2 Updates
Any changes to the application must be approved by COUHES prior to their im-
plementation. This includes personnel changes; new personnel must provide docu-
mentation of having completed the human subjects training. Renewals must also be
approved by the committee if the experiments extend beyond the original time period.
All experimentation must stop until the renewal is approved by the committee. Our
experiments extended beyond the original time frame and a renewal was approved.
See appendix A.4 for the change of date request and appendix A.5 for the continuing
review questionnaire required when continuing a protocol beyond the original end
date.
3.4 Protocol
The process for collecting data includes recruiting subjects, consenting subjects,
screening subjects, skin preparation, instrumentation, activities and follow-up.
3.4.1 Recruiting
The initial subjects recruited were members of the lab. An advertisement approved
by COUHES was placed around various locations on campus. Though approximately
10 people responded, not one of them successfully enrolled in the study. The primary
means of recruitment ended up being through the network of the investigators. The
lack of compensation prevented a more general appeal. See appendix A.2 for the
recruitment flyer.
3.4.2 Consenting
Potential subjects were given a copy of the consent form prior to being consented,
which allowed them to read it over carefully. The subjects were given a tour of the
study setup if they desired and then reviewed the consent form and signed it with
one of the PI's named on the COUHES application. Documentation was given to the
CRC before any experiments started. See appendix A.3 for the consent form.
3.4.3 Screening Subjects
Before starting each of the experiments, the study nurse evaluated the health of each
subject by taking vital signs. Each subject was also asked a series of questions to
ascertain that they were in the proper physical and mental condition to undergo the
testing, and that they knew what to expect during the testing.
3.4.4 Skin Preparation
One of the factors that can significantly affect the results of ECG measurements is
the preparation of the skin directly under the electrodes. Hair and dead skin can add
noise. Male subjects were given the option of shaving before the experiment, or the
study nurse could shave a small patch on the chest with a disposable razor made for
this purpose. The skin was then buffed with a rough pad to remove a layer of dead
skin and encourage blood flow to the area. Finally, alcohol was used to clean the
area and was allowed to dry. Effects of the preparation could include itchiness and
discomfort for approximately one day, and was reduced by wearing lose clothing.
3.4.5 Instrumentation
After the skin preparation, the subject was instrumented in the following order.
Prototype device
Once the wearable device was switched to battery power, the memory registers of
the device were cleared and the electrode configuration set with the custom software.
The device was then removed from the USB cable, and the disposable electrodes
were snapped into all five electrode locations. The sticky side of the electrodes was
exposed by removing the plastic coverings, and the study nurse placed the device on
the subject's chest, with one side of the 'L' shape along the body's long axis on the
subject's sternum, and with the other edge at a right angle above the left breast.
Clinical ECG
With the device in place, the disposable electrodes connected to the clinical leads were
placed on the subject's chest. They were placed with the ground electrode directly
below the device in the center of the chest, the negative terminal placed directly
to the left of the top left device electrode, and the positive terminal placed directly
to the right of the top right device electrode. See Figure 3-4 for a picture of the
prototype ECG device and the clinical ECG leads attached to a subject's test. The
ECG leads were then wrapped to the subject's abdomen with Coban self-adherent
wrap to prevent excessive movement. Once the ECG was in place, the subject was
able to put on a shirt to wear throughout the experiment.
Figure 3-4: Wearable cardiac monitor and clinical ECG leads. On the left, the subject
has only the wearable device connected via sticky electrodes under the device. On
the right the clinical leads have been added in the same arrangement as the wearable
device to give the same ECG lead projection.
Respitrace
The two bands were placed around the chest and the abdomen of the subject to fit
snugly, but not tightly. The oscillator was then connected to the bands and fixed to
the body with Coban wrap to minimize movement of the components.
PPG
The pulse plethysmograph sensor was placed on the index finger of the left hand.
A piece of tape was placed around the sensor and finger to prevent the sensor from
rotating while the subject was in motion.
Portapres
To reduce the load on the subject, the belt containing much of the electronics and the
pneumatic pump was left on a cart close to the patient. The front-end unit was fixed
to the left wrist of the subject with the velcro band attached. The sensor was then
placed on the middle finger of the left hand and attached to the front-end unit. The
sensor was placed snugly, but not tight enough to induce pain during the experiment.
The Portapres was then initiated and calibrated. See Figure 3-5 for a picture of a
fully-instrumented subject.
Sling
To keep the finger with the Portapres sensor close to the level of the heart, the
subject's arm was placed in a sling, with care taken not to put excessive pressure on
the neck. The sling also served to prevent the subject's arm from moving excessively,
which would have introduced additional noise to the various instruments.
3.4.6 Activities
The subject was asked to engage in a series of activities, each of which was followed
by a short rest period. The blood pressure signal was recalibrated after each activity
Figure 3-5: The subject is wearing all physiological monitors. The PPG is on the
index finger and the Portapres on the middle finger. The Respitrace bands are around
the chest and abdomen. Underneath the subject's shirt the wearable device and one
of the clinical ECG electrodes are seen.
to ensure consistent accuracy. The subject performed the entire sequence of activities
twice in a row, with each set of activities lasting approximately 40 minutes.
The subject was first asked to lie down on a bed in the CRC room in the supine
position for 5 minutes. At the end of the 5 minutes the subject was helped into a
sitting position on the edge of the bed for another 5 minutes. The subject was then
helped to stand up for an additional 5 minutes. The subject was then asked to hop for
1 minute. This activity entailed repeatedly raising oneself on one's toes, and leaving
the ground only if the subject felt so inclined. After resting, the subject was asked
to move their left shoulder to engage the chest muscles underneath the electrodes to
stimulate muscle noise. The subject was then asked to perform a 10-second Valsalva
maneuver, which involves holding one's breath and straining to increase intrathoracic
pressure.
At this point the subject was helped onto a treadmill and the speed was slowly
increased to a comfortable walking pace. The speed for walking was usually around 2
mph. The subject was allowed to walk for up to 5 minutes, after which the speed was
increased to a light run, typically around 4 mph. The subject was allowed to run for
up to 5 minutes, with the option of stopping at any time. At the end of running, the
treadmill was stopped and the subject was allowed to recover for a couple of minutes.
The last activity was to simulate stair climbing by repeatedly stepping onto and off
the back of the treadmill for up to one minute.
After the subject had rested and any necessary adjustments were made, the set
of activities was carried out one more time. A typical record from an experiment is
seen in Appendix B.1.
3.4.7 Follow-Up
After the two rounds of activities were complete, the nurse once again took the vital
signs of the subject to ensure recovery to normal values. The subject was questioned
about the procedure and the device, and given the opportunity to privately share any
concerns with the study nurse.
3.5 Experiments
Approval for the study was granted in the fall of 2009, but delays prevented setup
until the spring of 2010. In March and April the clinical equipment was put in place
and in May it was tested. From May to July the prototype device was tested and
adjustments were made to the protocol to reduce noise. Starting in August, data was
collected. Due to technical problems with the prototype device, the testing had to be
suspended in October 2010.
3.5.1 Clinical Research Center (CRC)
The MIT CRC was established in 1967 with support from the NIH, to serve as a
resource for non-clinical investigators to translate their research. The center provides
the infrastructure including facilities, records and staff to support such research. We
worked closely with Catherine Ricciardi R.N., to carry out the experiments. The
center provided a controlled and safe environment for subjects to be instrumented
and perform simple activities.
3.5.2 Setup
As previously mentioned, the experiments were carried out at the CRC in a private
room with a bed, a treadmill, and all of the instruments. All electrical equipment was
placed on a portable cart. All sensors that need to be connected to control units and
power were connected via cabling, and the cart could be moved to follow the subject.
The cart was placed in between the bed and the treadmill on one side of the room, to
minimize how much the subject had to move between activities. See Figure 3-6 for a
picture of the setup in the CRC.
Figure 3-6: Experimental setup in the CRC. In the middle of the figure is the cart
with all of the equipment for the physiological sensors and the data recording. In
order from left to right, the ECG leads, finger plethysmograph, respiration bands and
Finapres transducer are hanging from the pole. The bed on the right was used for
resting in the supine position, and the treadmill on the left was used for walking and
running.
3.5.3 Validation
Before starting experiments, it was important to evaluate the data from the vari-
ous instruments and optimize performance. This process was much easier with the
commercial equipment. With the clinical ECG we experimented with various skin
preparation techniques until we found the optimal noise reduction. The features of
the ECG, including P-wave, QRS complex and T-wave, needed to be clearly visible,
with minimal amounts of baseline drift and high frequency noise. During running
we felt it sufficient to see the QRS complex. We also attached the ECG leads and
the Respitrace oscillator to the body with Coban wrap after finding their movement
induced noise and sometimes resulted in a loss of the signal. The key with the Respi-
trace signal was to see the peaks and valleys of breathing, to be able to estimate
respiration rate. With the PPG we found that it was uncomfortable to have it taped
tight, but no tape resulted in a noisy signal during movement. Our goal was to see
the waveform shape, including the pulse reflection, during rest, and at least the peak
during running. There was little to adjust for the Portapres, and we were pleased
with the range of values it measured and the shape of peak, pulse reflection, and
valley.
3.5.4 Data Archiving
The data from the clinical devices were recorded directly on digital tapes during
experiments. After each experiment the data was read onto a PC, and the data from
the device was also downloaded. The physical information sheets from the experiment
were scanned and stored as a PDF. Each subject's data was stored by medical record
number, and no identifying information was kept outside the archive of the CRC. The
raw data was digitally archived and also translated into easy-to-read MATLAB and
WFDB formats.
3.6 Problems Solved
Issues that surfaced during experimentation included placement of the prototype
device, insufficient amplitude resolution in the device ECG, and insufficient sampling
rate of the accelerometer. By communicating with the device designers we were able
to have modifications made and thus obtain significantly improved performance.
3.6.1 Device Placement
It was necessary to settle on an electrode configuration that would work for all subjects
and be consistent throughout the experiments. The original idea had been to use
a Lead II configuration to capture the P-wave better, but this would have meant
that one side of the device would be aligned along the subject's sternum while the
other would run inferior to the subject's left breast. This configuration would have
potentially interfered with the anatomy and clothing of female subjects and was
abandoned in favor of a Lead I configuration. To be consistent, the electrodes above
the left breast were placed at the fourth intercostal space.
3.6.2 Insufficient ECG Resolution
The original amplitude resolution of the device had been set to 8 bits for convenient
data storage. The A-D converter was capable of 12-bit representation. Due to the
quantization noise seen in the data, the resolution was increased to 12 bits and the
storage scheme changed to accommodate the increased data rate.
3.6.3 Insufficient Accelerometer Sampling Rate
The original sampling rate of the accelerometer was 2 Hz, which captured slow move-
ments but was not high enough to capture quick movements, especially running on
the treadmill. The low sampling rate made it possible to store longer stretches of
data, but that was not necessary for this study. The rate was increased to 250 Hz to
match that of the ECG, which also made alignment of the signals simpler.
3.6.4 Design Feedback
One convenient aspect of the non-commercial device was that we could share our find-
ings directly with those developing the device, and they often were able to implement
solutions. The shorter the time delay in this feedback loop, the quicker issues were
resolved. I found that quick and accurate information passing was very effective, as
we often encountered problems the designers had not countered in their testing, and
they found solutions to problems we did not realize we had.
3.7 Future Devices
The main problem with validating the data coming from the device was that one could
not see the data in real-time. After recording the data, the only way to visualize it was
to download them to a computer, which takes time. Further time is spent resetting
the memory and restarting the device. So an experiment of 1 minute would have
an overhead time of around 5 minutes. Robustness was also a big challenge, as our
experiments wore down the devices and several had to be replaced.
3.7.1 No Feedback
One challenge was that when the prototype device was in operation, there was no
feedback to the study personnel regarding whether or not the device was collecting
data. The only way to determine whether data collection was proceeding properly
was to try to download the data at the end of the experiment and look at it. Since
the device was not designed to be particularly robust, it degraded over time. An
LED was available on the device and was programmed to blink when the device was
working properly. This did not give any information about the data; however, it did
indicate that the device was recording data properly.
3.7.2 Robustness
As mentioned, the device was a prototype design and was not designed to be particu-
larly robust. We discovered that normal handling of the device, particularly removing
it from the subject, resulted in enough wear and tear for the device to fail over time.
One hypothesis is that the ground drive circuit was too close to the edge of the de-
vice and solder connections eventually broke. The result was the data would get
corrupted with 60 Hz noise, or the device would simply stop working. The problem
with the noisy data was that we could not assess data quality until the data had been
downloaded at the end of an experiment.
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Chapter 4
Data
4.1 Subject Population
Subjects were drawn entirely from an academic population. All 10 subjects were male;
one female subject was tested, but the device failed and the data was not recovered.
The majority of subjects were students in their twenties, with one outlier. The
subjects were racially and physically diverse. All were in at least good health, with
several subjects in excellent health. Table 4.1 shows the ages, health state, exercise
level on a scale of 1-7 along with blood pressure and heart rate taken immediately
before testing. All exhibited normal vital signs during screening. All subjects were
informed prior to the experiments and freely consented according to IRB guidelines.
4.2 Data Representation Review
The "data deluge" is becoming a more common problem in medicine. The challenge is
to take high dimensional data and long recordings, and represent it in a way that can
be understood by the human mind. Typically the way such information is presented
in the literature is in 2D tables or time series representations or well-established plots
such as ROC curves or power spectra. The idea is to give a general feel for the data
so that specific details of interest can be recognized and studied more closely.
Whether trying to condense data into something a doctor can use, or trying to
Table 4.1: Subject
Subject ID Age General Health Ex. Level Sys/Dia HR
11928 38 Excellent 4 118/76 64
14673 25 Excellent 6 114/62 68
14863 30 Excellent ? 122/78 72
14864 22 Excellent 4 118/60 72
14865 57 Good 3 112/70 72
14868 19 Excellent 4 104/60 58
14869 25 Excellent ? 112/76 70
14870 31 Good 4 128/68 72
14871 27 Excellent 4 104/60 52
14874 27 Excellent 4 104/60 56
include snapshots in a thesis, this is a difficult problem. Here I will give several
snapshots that would not be practical in a medical setting. Summary statistics can
be generated, but still only provide one angle of information.
4.3 Representative Data
All of the physiologic signals measured are periodic or quasi-periodic in nature. Each
period can be examined individually to classify the shape of the beat in time or to
extract specific features. One can look for changes from beat to beat, and also for
what remains invariant. In this chapter there are several plots including a variety of
signals from a variety of subjects performing various activities. Some specific things
looked at are noise and patterns that depend on activity. The data is selected here
to highlight different features that are significant.
4.3.1 ECG
All of the plots include two ECG recordings, one from the portable device (red) and
one from the clinical device (blue). The magnitude of the red curve is accurate in mV
on the scale, but the clinical magnitude could not be calculated in mV accurately. It
is shifted up to display the two together.
Population
QRS
Figure 4-1: The representation of the electrocardiogram during one heart beat shows
the major features.
As mentioned in the background material in section 2.5.1, the shape of the ECG
will depend on several factors, including equipment such as electrodes, placement of
electrodes and electronics. Essentially the same electrodes and projections were used
for both the portable and clinical devices, so the difference between the two should
be largely due to the devices themselves.
The cartoon in Figure 4-1 shows the basic shape of an ECG, with the P-wave
providing information about the atria, the QRS-complex providing information about
the depolarization of the ventricles, and the T-wave providing information about
the repolarization of the ventricles. The various segments and intervals are notable
features giving insight into the circuitry of the heart. These features can be seen
in most of the data below, though longer stretches, usually 20 seconds long, will be
shown to demonstrate patterns.
The supine data in general was of excellent quality as seen in Figure 4-2. The
largest source of noise while supine was 60 Hz noise that showed up strongly in the
portable device because it did not have a good notch filter. It may have been that
more 60 Hz interference was coupled into the body because the body was in contact
with the bed over a large area. It is also likely that the equipment used for recording
14870 - ECG - Supine
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Figure 4-2: These two figures demonstrate classic ECG waveforms representative of
those obtained in the supine position, from the clinical device (blue) and the portable
device (red).
was causing problems because it was around the same height as the bed and in close
proximity to it. In general, this problem is very solvable, and applications where the
subject is laying on their back should produce very clean data. It should be noted
that the bottom two plots in Figure 4-3 are from the same subject. It was found that
the prototype device was not very robust to noise, even within an experiment, which
would be important in a final device.
Some of the data while sitting also had 60 Hz noise (see Figure 4-4), but most of
it was also very clean. This data also could be useful since people spend much of their
time sitting down. The standing data was similarly clean, except for brief stretches
of noise as seen in Figure 4-5. This noise could be from muscle movement due to the
subject shifting their weight, from talking or coughing, or something else.
The Valsalva maneuver is a simple, yet interesting test used to probe the au-
tonomic nervous system. It involves straining, which requires muscle effort in the
thoracic cavity, resulting in electrical activity in the chest which is picked up by the
ECG. As opposed to the 60 Hz noise seen before, this muscle noise shows up in both
the clinical ECG and the portable device. Though there is significant noise, the heart
rate can often still be extracted. The saturations in the bottom right plot of Figure
4-6 may be due to loose electrodes.
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Figure 4-3: All of the plots show the signal corrupted with 60 Hz noise much more
pronounced in the portable device. The amount of noise varied widely between sub-
jects and within a single subject's record. It appears that, depending on the state of
the prototype device, the proximity of our recording equipment, and position of the
person, more or less noise was present. Note that the two bottom plots are from the
same subject.
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Figure 4-4: The 60 Hz noise sometimes showed up while sitting
of the left plot, but this went away when the subject stood up.
data captured while sitting looks like that on the right.
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Figure 4-5: The top plots are more typical and show classic ECGs, with little artifact.
There was artifact, as noted in the bottom plots, which often had high frequency
characteristics, likely muscle noise.
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Figure 4-6: The Valsalva maneuver is important in cardiology, but can show up noisy
on the ECG. Depending on the degree of straining, muscle noise is present as high
frequency content. The bottom plots are quite corrupted with the bottom right plot
having a major error in the portable device.
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The hopping varied significantly between subjects. Some chose to rise up on
their toes and some left the ground with decent force. The top plots of Figure 4-7 are
unusually good and are likely the result of light hopping. The middle plots are typical,
with baseline wander the result of tugging on the electrodes in the experimental
device, but not in the clinical case where only lightweight wires were connected to
the electrodes. The bottom right plot is a little perplexing and may be muscle noise.
The arm movement exercise also varied significantly among subjects. They were
instructed to move their left arm to flex their chest muscles and add muscle noise.
The top plots in Figure 4-8 show very clean results, which again may be because the
subjects did not flex very strongly. The lower plots show the signature high frequency
noise from muscles. It is possible to see how often the subjects were moving the muscle
by noticing the periodic bursts. The baseline wander, which is especially noted in the
bottom right, is likely the result of stress being put on the wires.
In general the ECGs taken during walking looked very good, as seen in the top
row and bottom left plots in Figure 4-9. The bottom right had an unusually large
amount of noise. The minimal amount of noise during walking is very encouraging
because medium intensity exercise physiology tests can be performed with relatively
little noise.
The typical running ECGs are seen in the top row of Figure 4-10. The middle
row shows more baseline wander likely due to loose electrodes or perspiration. The
bottom left plot shows a very noisy signal in the portable device. With filtering, it
was usually possible to extract the heart rate, but there were some areas where this
was not possible. The bottom right plot shows saturation, which occurred because of
damage to the device during the experiment. Sometimes the device would recover,
but again it showed the lack of robustness of the device.
The recovery period after exercise is very important because it provides insight
into the autonomic cardiovascular physiology and is usually cleaner data than during
activity. The data usually looked very good, but the most common problem was
baseline wander, as seen in Figure 4-11, likely due to perspiration. In an adaptive
filtering scheme it may be good to pay particular attention to baseline wander after
14874 - ECG - Hopping
14673 - ECG - Hopping 14863 - ECG - Hopping
14869 - ECG - Hopping 14871 - ECG - Hopping
4 4
1.5 
35
3 2.52s
0.52
1975 1380 1385 1390 1395 150 1255 1260 1265 1270
Figure 4-7: The plots represent the best (top row), typical (middle row) and worst
(bottom row) ECGs during hopping. Noted in the typical data is that the clinical
ECG performs better. It is likely that the mass of the device results in more force
pulling on the electrodes, which leads to greater motion noise. The high frequency
noise is likely muscle noise, which may vary according to the subject's body or the
placement of the electrodes.
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Figure 4-8: The plots represent the best (top row), typical (middle row) and worst
(bottom row) ECGs during arm movement. The top plots are surprisingly clean while
the middle plots show noise that is more expected - high frequency noise from the
pectoralis and surrounding muscles picked up during each movement. The bottom
row is of very poor quality; and it should be noted that the bottom right and middle
right plots are from the same subject.
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Figure 4-9: The ECG data during walking was generally very clean. The top plots
and the bottom left show typical data, while the bottom right is an exception. The
noise shows up in both devices, but is a little worse in the portable device. It may
be that the subject held their trunk differently, so that muscle noise confounded the
signal.
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Figure 4-10: The top plots show representative data during running, the middle plots
show noisier data, and the bottom plots are segments that are confounded by severe
noise and artifact. There were some stretches like those on the bottom right that
were unusable in one channel.
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Figure 4-11: The recovery period after running was usually much cleaner than during
running. Sometimes there was significant baseline wander, which may have been from
loosening of the electrodes during running or the result of a poorer contact due to
perspiration.
exercise to see if anything has changed with the electrode contact.
The stepping data overall looked very good (see Figure 4-12). Climbing stairs is a
common daily activity, which could be good for stimulating cardiovascular physiology.
In general there were a few types of noise: baseline wander due to contact prob-
lems such as motion, loosening of electrodes, or perspiration; high frequency noise
likely due to muscle motion underneath the electrodes; and 60 Hz noise, which can
easily be mitigated through better filtering. The relatively low noise levels are very
encouraging, given the physical activity taking place, and it should be possible to use
the data to correlate cardiovascular changes with changes in activity.
It could clearly be seen that heart rate increased during periods of activity such
as running. Something that is a little more subtle is the effect of breathing on the
envelope of the ECG signal. Other changes may require longer stretches of data to
extract the physiological importance.
4.3.2 Arterial Blood Pressure
The arterial blood pressure (ABP) waveform contains a wealth of information about
cardiovascular state. Unfortunately it is difficult to measure, especially in an ambula-
tory environment. Each beat is less complicated than the ECG, as the pressure wave
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Figure 4-12: The stepping data was usually a little noisier than the walking, but
usually not nearly as bad as running.
only contains information from the left ventricular contraction and relaxation cycle.
The basic waveform in one cycle can be seen in Figure 4-13. Although the shape
alone is informative, the absolute values of the measurement are very important and
the data presented is calibrated and displayed in units of mmHg.
The data collected is of the shape of the cartoon shown with variability in height
of the reflected wave, which is sometimes completely absent. The majority of the time
the ABP waveforms look like Figure 4-14 when the subject is not moving. There are
occasional noisy segments, usually due to motion, as seen in Figure 4-15, but there
were also areas of significant noise that were difficult to explain, as in Figure 4-16.
Physiologic variability is also an important factor. For example, Figure 4-17 shows
two examples of significant physiologic variations probably due to the control system
of the subject acting to control recovery from exercise. There is information in these
variations that have been studied extensively with ECG, such as heart rate variability,
but the relative difficulty of collecting ABP waveforms has limited the same kind of
analysis with blood pressure signals.
During motion, the signal degrades somewhat. While walking, there is actually
very little change in the structure and amount of noise (see Figure 4-18). There are
interesting differences between the two subjects: though the heart rates of the two are
very close, as well as the diastolic pressure, the systolic pressures differ by 40 mmHg.
Diastolic J i c
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Figure 4-13: A schematic representation of blood pressure during one heart beat. The
minimum on the left is the diastolic value, which then rises quickly during systole until
it reaches a maximum (systolic value). The smaller bump to the right is the reflection
of the pressure wave.
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Figure 4-14: On the left the subject is supine, with very periodic beats and a small
reflected wave. The modulation on the envelope is likely due to breathing. On the
right the subject is standing, with much more of a reflected wave noted, and a more
variable baseline and pulse pressure. The majority of the data looks like the image
on the right.
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Figure 4-15: The noise in the left figure originates from movement of the sensor
when the subject is moving their arm. The noise is within physiologic limits, but
is obviously out of place and throws off the pulse pressure especially. On the right,
during a Valsalva maneuver, the sensor stops working. It is not clear why, but it may
have been the blood pressure dropping too low in a short period.
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Figure 4-16: Sometimes the noise is hard to understand as it shows up in a relatively
quiet period and doesn't necessarily show up on the accelerometer as motion since
the accelerometer is on the chest and the ABP transducer is on the finger. Sudden
and short high frequency bursts may be a quick motion and the drop in all signal on
the right may be when the sensors do not detect anything.
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Figure 4-17: Illustrations of physiologic variability. The subject on the left had a
peculiar heart beat pattern that varied significantly. This example shows the heart
rate slowing down significantly in the middle, and both pulse pressure (i.e., systolic
minus diastolic) pressure and mean blood pressure rising. On the right there is a lot
of wander while the subject is recovering from running on the treadmill.
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Figure 4-18: These plots of ABP during walking are very typical. There is some
variation noted, but not a large amount of noise. The reflected wave can sometimes
be noticed and is quite variable.
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Figure 4-19: ABP during running. The top left figure shows a lot of variability and
the top right shows less frequent, but greater variation. The source of each of these
is uncertain, but important to recognize. The bottom plots exhibit less variability. It
is noted that the reflected wave is often not visible.
Running changes the signal significantly, probably because of the tendency to
swing one's arms during running, which will change the pressure and add motion
artifact (we tried to immobilize the arm with the transducer attached to it by placing
the arm in a sling, but there was still some motion). The heart rate is clearly higher
during running (Figure 4-19) and the reflected wave is often absent. There are noise
sources and variations that are very peculiar and difficult to explain. It should be
noted that subjects were running at different speeds and had different gaits, which
would result in very different patterns. This variation is one of the challenges of
measuring blood pressure at the finger. The majority of the noise likely came from
moving the finger.
14864 - ABP - Running
4.3.3 Respiration
Respiration is inherently a more variable signal because it is not as periodic as auto-
nomically driven physiology. The respiratory system can operate automatically, but
can also be overridden; there is no strict pattern. Also, breathing during speech is
quite different than silent breathing. The non-periodicity makes it harder to interpret,
and harder to derive quantities such as respiratory rate.
Respiratory rate can still be extracted with some degree of confidence. The depth
of breathing may also be estimated by the amplitude of the signal. There is much to
be learned from interpretation of the signal; it is just harder to do automatically.
A rather regular respiratory signal is seen on the left in Figure 4-20. Particularly
during rest in the supine position, the signal was fairly periodic and stable. The
amplitude corresponds to depth of breath and less regular breathing is noted on the
right in Figure 4-20. The last breath on the right is a particularly deep breath. The
amplitude is a relative value that depends strongly on body position. Figure 4-21
shows what effect a shift in body position has on the signal. Another interesting
activity that shows up on the respiration is speech. It is possible to pick out intervals
of speech, which have a distinctly linear characteristic, as seen in Figure 4-22.
With increased metabolic demands, the signal appeared to change more dynam-
ically, as noted in Figures 4-23 and 4-24. It is also possible to see what activity the
subject was engaged in based on the noise characteristics, but that was very device-
dependent. During walking there are small deviations on top of the respiration signal
and during running those deviations are much larger and more regular.
The device used was an older Inductotrace, with connectors that were susceptible
to motion noise. For this reason the noise was particularly noted during running, and
was very periodic. It was also noticed that in different positions, there were different
contributions from the abdominal belt and the chest belt. For this reason, the sum
of the two was used as a more consistent estimate of overall respiratory activity.
During increased metabolic demand, there will necessarily be an increase in oxygen
needs. Increasing the flow of oxygen involves two mechanisms, namely increasing the
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Figure 4-20: On the left is an example of quite regular and noise-free respiration. On
the right is a much more typical recording with the subject taking irregular breaths
of varied intensities, with the last breath being much deeper than the previous ones.
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Figure 4-21: On the left the subject goes from standing up to a supine position. The
ripple is the actual breathing signal, with the exponential decay of the local average
being an artifact of the change in position and relative change in chest diameter. On
the right the opposite is happening, when the subject goes from the supine position
to sitting up.
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Figure 4-22: The figure on the left shows periodic breathing with occasional inter-
ruptions that appear to be descending linearly. These regions correspond to talking,
when the expelling of air may be more linearly controlled to maintain constant air
flow. On the right is a more drastic example, with very quick breaths in and then
linear regions corresponding to talking. This subject typically can talk for around 5
seconds before needing a breath.
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Figure 4-23: On the left, the breathing rate is similar to that at rest,
regular intervals, but more noise present due to the transducer. On the
more noise is present.
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Figure 4-24: The respiration rate has increased, but the noise has also increased
drastically. The high frequency noise corresponds to the impact of the foot with the
ground causing the transducer to move.
rate and the volume per breath. The respiration rate increases from 0.5 Hz in the
supine case to 0.6-0.7 Hz during running. Though it is difficult to generalize the
amplitude between subjects, it can be seen that during running there is also greater
depth of breathing, resulting in more volume per breath.
4.3.4 PPG
Pulse plethysmography (PPG) is inherently a noisy signal; because of the optical
components, it is very sensitive to motion. However, it is excellent for measuring
heart rate, because only the maximum needs to be detected, and the implementation
of hardware and software for this task is very straightforward. The pulse is seen in
the dilation of the artery in the finger, as the pressure wave propagates and causes
the blood vessel walls to expand. The little notch is the reflected wave, but is not
always seen. The magnitude, frequency and morphology will all change, depending
on the activity taking place. A very clean waveform is seen in Figure 4-25 on the left
and a more typical waveform is on the right. More variation is noted in Figure 4-26
during standing and walking.
The most obvious noise is seen in Figure 4-27, where the signal in the plot on
the right goes flat for a short period. This often happened during running, and may
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Figure 4-25: PPG from two different sitting subjects. On the left the recording is very
periodic, with little variation. On the right there is more variation, which is more
typical, including change in baseline, amplitude, and height of the reflective notch.
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Figure 4-26: The standing subject on the left shows a greater amount of variation,
with little or no reflected wave detected. The heart rate is also greater than for the
sitting subject in Figure 4-25. The figure on the right is very typical, with a little
less variation in the amplitude, but showing variety in the notch during motion.
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Figure 4-27: On the left the recording is typical of the PPG during running, with no
notch noticeable and a fair amount of variation. On the right is significant variation,
with some failure modes where the signal goes flat over time. This was not a rare
occurrence during movement.
have been due to too much motion resulting in no signal from the transducer. The
variation in height could be physiological or could be noise. The amplitude is not
presented with units because a voltage is what is measured, which correlates with
the volume of blood in the finger; the ordinate can be viewed as a rough estimate of
artery diameter.
While sitting, the values approximately range from .25-.65 (there will be variation
in between subjects) in arbitrary units. It appears that walking does not change
the amplitude significantly, but during running the amplitude is much less, with the
systolic value significantly lower and the diastolic value slightly higher. This corre-
sponds well with the known fact that during exercise the resistance in worked muscles
decreases, whereas in areas that do not require increased blood (and in particular the
fingers, where the transducer is), the resistance is increased by decreasing the diam-
eter of the arteries.
4.3.5 Accelerometers
The following plots show the 3-axis accelerometer data. In green is the y-axis (parallel
to gravity), in brown the x-axis (perpendicular to gravity and in the plane of the
chest), and in purple the z-axis (perpendicular to gravity and the plane of the chest).
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Figure 4-28: This figure is a good example of a complete record of accelerometer data.
The first transition is from standing to supine where the z-axis transitions from close
to 0 G's to almost 1 G. The values are very similar between sitting and standing,
though the angle of the body may change slightly, accounting for the slight difference
between the x and z axes. The solid regions of larger magnitude are oscillations
packed closely. Note that there is always a 1 G gravity component present.
The data was originally sampled at 2 Hz with the first three subjects, to simply get
an idea of body position. It was then switched to 250 Hz to match the ECG, in
order to capture the details of movement like running. One thing to keep in mind is
that gravity will always be present with a value of 1 G, though it may be distributed
between the different axes with appropriate trigonometric terms. It should be kept
in mind while interpreting the accelerometer data that they are indeed accelerations
and not positions or velocities (which are perhaps more intuitive to conceptualize).
Figure 4-28 shows the three axes of the accelerometer over the complete set of all
activities performed twice. The highest variation is seen in the axis parallel to gravity
(green) because of the up and down motion during jumping and running. Figure 4-29
shows six other examples of complete accelerometer signals. The same basic pattern
is followed, though the amplitude of variations differs from subject to subject as do
noise levels. Figure 4-30 shows acceleromter signals for several different activities
from the same subject, but is representative of all subjects tested.
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Figure 4-29: The general pattern of the data is consistent across the subjects, though
variations are noticeable. For example, 14673 bends over a little throughout the
activities, especially hunching over while sitting. Subject 14869 on the other hand
has very erect posture and exerted more effort during hopping. Subject 14870 exerted
much more effort during the second time jumping. There were a few artifacts, such
as the large deviations seen in 14869 and 14871. The large presence of the x and z
axes in 14874 may have been a storage error.
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Figure 4-30: The various activities are shown on shorter time scales in one subject.
The transitions from standing to supine, supine to sitting and sitting to standing
are all captured in the top left plot. Arm movement is seen in the top right, with
little activity in the y-axis, and most in the x-axis. Hopping, middle left, shows
most activity in the y-axis, with distinct spikes where the hop takes place, and with
some other movement in between each hop. Walking, middle right, shows a pretty
consistent pattern in each axis with the most interesting in the y-axis; there appears
to be a bump with a sharp spike down interrupting it. Running, bottom left, has a
much smoother shape because it is less complex in terms of specific impacts. Stepping,
bottom right, is periodic, but has much less defined period shapes and a lot of variety.
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4.4 Summary Statistics
Overall the quality of the data was impressive and could be used for extended analysis.
It was also encouraging that many of the noise issues could be solved with better
filtering and more robust designs. It could be expected that during periods of high
activity the quality would go down, as was seen especially during running. It was
noticed that during some activities like running, arm movement and recovery, there
were specific failure modes that may possibly be addressed dynamically. In conclusion,
the future is very promising for wearable physiologic signals.
100
Chapter 5
Analysis
This chapter will focus on three areas of signal analysis: signal processing, modeling
and sensor fusion. I first review several signal processing techniques and some popular
algorithms implemented for physiologic signals. One example of signal processing I
explored was signal quality assessment. Regarding models, I review the Windkessel
model which I applied to my data to estimate derived quantities that may be more
relevant to clinical practice than raw data. Lastly I discuss sensor fusion, including
how data from multiple sources can be represented together and how different sensors
can increase the accuracy of derived quantities.
5.1 Signal Processing and Algorithms
Clinicians have traditionally looked at waveforms directly, but efficient algorithms
and signal processing techniques have automated much of that work, and are even
able to detect subtle changes the human eye is not able to. I will review here some
common techniques and applications. ECG waveforms are perhaps the oldest and
most commonly studied physiological waveforms that are processed, and much of the
literature focuses on this signal. I will therefore focus on this specific measurement.
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Filtering
Filtering is most commonly used as a pre-processing step to clean up data before
applying other techniques like feature extraction or thresholding. It can be done as
a batch process after data is collected, or in real time on microprocessors, a technol-
ogy that has been implemented for use with the ECG for more than 25 years [42].
Removing noise can be done with standard FIR filters or with adaptive filters [43].
Kalman filtering is an example of computing the best estimate of noisy data [44]. A
different application of filtering is to use filter banks to divide the signal into different
frequency bands for detection of various characteristics [45]. Virtually all algorithms
will include some form of filtering.
Transforms
Transforms are a powerful tool for representing data in different domains. The Hilbert
transform for example can be used for QRS detection [46]. Another commonly used
transform on which QRS-detection is based is the wavelet transform [47], [48]. Curve
length transform is yet another transform used with QRS-detection [49]. The Fourier
transform is used to visualize data in the frequency domain and is the most commonly
used, with numerous applications.
Spectral Analysis
Examining physiological signals in the frequency domain can provide an important
angle from which to examine data. One example is analyzing high frequency content
for assessing risk of ventricular tachycardia [50]. This technique is commonly used
in cardiovascular signals, with a large body of literature examining heart rate in the
spectral domain [51] [52] [53].
Feature Extraction
With an ECG signal, feature extraction is used to find distinct repeating (or rare
but relevant) morphological features, particularly the high frequency QRS complex,
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to calculate heart rate [54]. More specific feature values can be extracted for more
detailed analysis and classification [55]. Features are typically extracted from the
time-domain signal, but can also be taken from other transform domains. Other
areas of application include the EEG, where features are not as distinct and research
on extraction is under development [56].
Algorithms
When a task is well-defined and its importance has been established, the problem
becomes algorithm development. New algorithms may involve techniques already
mentioned, or may lead to the creation of new techniques. QRS-detection is a promi-
nent example. The task is well-defined, with the input being the recording on one or
more ECG leads and the output being a series of event markers indicating the start
of the QRS complex. Several effective approaches with these inputs and outputs have
been implemented [57, 58]. A higher level approach in general is to combine various
algorithms in an attempt to increase accuracy [59].
A recent boost to signal processing in the physiological domain is the growth of
physiological data repositories such as the Physionet project [60]. By providing data,
algorithms can be tested and readily compared. Without such a resource, the data
collection and storage would be an enormous barrier to algorithm development.
5.2 Models and Estimation
Modeling is used to approximate physical behavior in a mathematically rigorous man-
ner. Such models provide insight into the dynamics of a system and allow for the
estimation or prediction of unknown variables. Such estimation is valuable when an
unknown variable is difficult or impossible to measure. An excellent example of the
advantage of estimation through modeling is the estimation of intra-cranial pressure
(ICP). Measuring ICP is very invasive and is only done in severe cases. By build-
ing a model based on variables that are much easier to measure, Kashif et al. have
demonstrated accurate estimation of ICP without using invasive methods [61]. In the
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cardiovascular system, variables that are very difficult to measure, but provide intu-
itive information into the cardiovascular state of the patient are cardiac output (CO)
and total peripheral resistance (TPR). Invasive methods are available for measuring
CO accurately and are commonly used in critical care settings. There is no method
available to measure TPR. This section explores model-based methods for estimating
these two important variables non-invasively and in an ambulatory environment.
5.2.1 Windkessel
I use a very simple cardiovascular model, the Windkessel model. It is a three-element
representation of the cardiovascular system using lumped components. The circuit
equivalent is seen in Figure 5-1, with a current source representing the instantaneous
CO, a linear capacitor representing the arterial compliance (AC), which stores energy
with sufficient pressure, and a linear resistor for the total peripheral resistance (TPR),
which is mainly comprised of the resistance of the arterioles. The arterial blood
pressure (ABP) correlates to voltage in the electrical circuit.
ABP
co AC; TP RCAC
Figure 5-1: Circuit representation of the Windkessel model. CO - Cardiac Output,
ABP - Arterial Blood Pressure, AC - Arterial Compliance, TPR - Total Peripheral
Resistance.
The differential equation relating the elements of the circuit is
dABP(t) ABP(t) (5.1)CO(t)z= AC* dt+ TPR1dt T PR
where AC and TPR are assumed to be constant over time. Both ABP and CO
have well known time-varying patterns as seen in Figure 5-2. It can be seen from the
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ABP waveform that there is a reasonable approximation to a single exponential decay
during the transition from systole to diastole, which agrees well with Equation 5.1 for
any interval in which CO(t) = 0. The time constant of the system is r TPR * AC.
ims 8?3*oft Prms*r i
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Figure 5-2: On the left is the profile of arterial pressure during one heart beat, and
on the right is the profile of cardiac output during one heart beat. It is noted that
the CO has a very steep rising slope and falls off with finite duration. Taken from
[62].
The CO waveform is a short pulse which rapidly increases with the onset of systole
and the opening of the aortic valve, has a short but finite duration, and drops back
down to zero when the aortic valve closes. The simplest way to model this behavior
is with an impulse of area equal to the stroke volume (SV), which is the area under
the CO(t) waveform in one beat. The main limitation of this approximation is that
the CO has finite width, and therefore some of the time dynamics of the CV system
will be compressed, but it is a relatively minor effect.
The AC term described above is the aggregate compliance of the arteries that the
blood leaving the heart sees. By definition, the compliance is the change in volume
per change in pressure, or in our case (under the impulsive approximation, which
implies all flow is absorbed by the compliance at the instant of ejection):
AC = SV/PP (5.2)
Given the structure of the arteries, it is readily apparent that the assumption of a
linear compliance is open to challenge. The compliance will be determined by the
given volume in the vessel as well as the smooth muscle tone of the artery [63].
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Also, the characteristics may not be constant. Despite these obvious limitations, it
may be reasonable that the compliance is fairly linear over physiologically-relevant
values and fairly constant over the time scale of our tests. Long-term changes in
arterial compliance have been linked with age, exercise training and certain diseases
[64][65][66]. Change in compliance is clearly an important topic, but not relevant on
the timescale of hours or days which this work explores and is simply assumed to be
constant.
The mean (as opposed to instantaneous) cardiac output is defined as the volume
of blood exiting the heart in a given time period, or more specifically how much blood
is ejected from the heart on each beat, multiplied by the number of beats per minute.
We then arrive at the following equation (now and in all that follows we use CO to
denote mean rather than instantaneous cardiac output):
CO = AC * PP * HR (5.3)
Since AC is assumed to be relatively constant, the above equation shows that cardiac
output is proportional to the product of pulse pressure and heart rate:
CO a PP* HR (5.4)
Both pulse pressure and heart rate can be derived from the blood pressure wave-
form. HR can also be derived from the ECG and PPG waveforms. Equation 5.4
provides a very simple way to estimate (to within a scale factor) a difficult-to-measure
but import and physiological value from two relatively accessible values.
Referring back to the Windkessel model, another valuable quantity can be esti-
mated as well. The average of the voltage in the circuit over a heart beat can be
divided by the average current to obtain the value of the resistor. TPR can then be
estimated as
TPR = meanABP/CO (5.5)
Since compliance is difficult to measure and we never calibrate, the cardiac output
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estimate in Equation 5.4 has no physical units. The same is true for Equation 5.5
because CO is one of the terms. Values reported are therefore relative, and valuable
over a subject's record, but cannot necessarily be used to compare values among
different subjects.
The main advantage of this estimation approach is its simplicity. Four values
need to be extracted from each beat: the value of ABP at systole; the value of
ABP at diastole; the mean ABP over the entire beat; and the distance between the
same fiducial points on two consecutive beats, e.g., time of systole. With those data
points, it is simply a matter of arithmetic operations to calculate CO and TPR. Such
an approach could easily be implemented for execution in real-time with an on-board
microprocessor. See 5-3 for two examples of such estimates.
5.2.2 Activity
Uptake of oxygen in the body is the best indication of metabolic needs and the load
on the heart. Estimating this value has long been identified as important, but is a
challenge. The most direct method is measuring chemical concentrations of air from
the subject during exercise. This is a cumbersome method and a host of estimates
have been developed. A convenient way to represent change in metabolic activity is
with the unit MET, which is the body's metabolic equivalent of power. One MET
is equal to resting metabolic rate, which is approximately 3.5 0 2/kg/min. Less than
3 METs is considered light activity, 3-6 METs is medium, and more than 6 METs
is vigorous [21]. A compendium of different activities has been compiled for quickly
estimating the demands of a variety of activities, from running to yard work, an
example of which is seen in Table 5.1 [67].
Accelerometers have long been seen as an attractive option for such estimations
[68]. In 2000 an article examining differences between MET values and estimated
METs from accelerometers showed discrepancies ranging from 30-60% [69]. Later
studies showed that a tri-axial accelerometer matched reasonably well with doubly
labeled water measurements [70]. It appears that accelerometers can be used for
approximations of energy expenditure, but a single model has not been found to fit
107
14863
1.2-
1
*0.8
20.6-
-0.4-
0.2
0 1000 2000 3000 4000 5000
Time (s)
14864
1.5
0.5-
00 1000 2000 3000 4000 5000
Time (s)
Figure 5-3: Estimates of CO and TPR for two subjects. The CO is in blue, the TPR
in green and the red will be explained in the next section. The plots exhibit some
noise, but show consistency in responses, which held for all 10 subjects.
well with actual METs. Studies have turned to evaluating accuracy and applications
with respect to specific populations, stratified by age, sex or medical condition [71,
72, 73, 74]. For other estimation techniques, see Ainslie et al. [75].
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Table 5.1: Running METs
Description METs
jog/walk combination 6.0
jogging, general 7.0
jogging, in place 8.0
running, 4 mph (13 min/mile) 6.0
running, 5 mph (12 min/mile) 8.3
running, 6 mph (10 min/mile) 9.8
running, 7 mph (8.5 min/mile) 11.0
running, 8 mph (7.5 min/mile) 11.8
running, 9 mph (6.5 min/mile) 12.8
running, 10 mph (6 min/mile) 14.5
running, 11 mph (5.5 min/mile) 16.0
running, 12 mph (5 min/mile) 19.0
running, 13 mph (4.6 min/mile) 19.8
running, 14 mph (4.3 min/mile) 23.0
running, cross country 9.0
running, stairs, up 15.0
The interest of our study was not to track metabolic demand accurately, but
to produce a general indicator of activity. In deciding how to represent activity,
other variables besides the relationship with oxygen uptake should be considered,
including necessary input variables and computational complexity. We decided on
a very computationally simple method using only the data from the accelerometer.
Additional information such as height, weight and gender could be useful, but was not
incorporated. A more complicated approach would be to identify activities with the
accelerometer and relate them to the compendium in Table 5.1. Then an adjustment
could be made according to the energy in the accelerometer signal.
The physical activity (PA) estimation score used was the square root of the sum
of the variances of each of the three axes of the accelerometer over a sliding window:
PA- = - +oY +w O (5.6)
with a window size of four seconds, and each window overlapping the next by one
second. Aside from the computational simplicity, this measure carries physical units
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Figure 5-4: In color are the data from the 3-axis accelerometer over the course of
one set of interventions. To aggregate this information into a single activity measure
(plotted in black), whemte square root of the sum of the variances from each axis
over a 4 second window.
of G's and excludes the gravity component, as long as body orientation does not
change significantly over the window. The PA gives valuable insight into the relative
load on a given subject over time, but cannot be confidently used to quantitatively
compare activity across subjects.
5.2.3 Signal Quality Assessment
Background
Signal quality or its opposite, signal abnormality, are of interest in large data sets
because they provide information on which parts of the data to examine. If the
data vform ise, it should be ignored. Noiseless signals should be given substantial
attention and need no filtering. Most data falls in between these extremes, and signal
quality indicates to what extent. Previous methods have been based on how well
different algorithms detect the same events [76] [77]. The key is identifying when the
signals deviate from some normal. If noise sources are decoupled, shared information
is physiologic and this approaches works well. Another approach is to examine when
a waveform is likely not signal, based on its characteristics.
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Signal Abnormality Index
I looked at deviations that were not physiologic by using the curve length transform
(CLT) defined as
i+w
CLT(w, i) = E Atk + Ayk, (5.7)
k=i
where w is the length of a sliding window, Atk is the time difference between con-
secutive data points and Ayk is the difference in the magnitude between consecutive
data points [49]. Using a window of appropriate length, the CLT was applied to the
signal of choice. It can be assumed that physiological signals should be smooth and
change on a relatively slow time scale, whereas noise will be higher frequency in na-
ture, due to electronics or movement for example. The frequency of changes therefore
indicates how likely the signal over a window is actually physiologic. The CLT can
also pick up the magnitude of the deviations from a smooth signal. One advantage
of this approach is its simplicity, involving only standard arithmetic operation. It
could be run continuously and used to decide whether to store data or whether to
filter or do further processing in real-time or decide what data to transmit. Figure
5-5 shows the relative noise level throughout the test for one subject, presented as a
signal abnormality index.
5.3 Sensor Fusion
An area of physiological monitoring that has garnered increasing attention is that of
combining information from multiple sensors to increase the usefulness of the data.
Three examples of sensor fusion with our monitors and data are given.
5.3.1 Combining Multiple Signals
Traditionally the combination and evaluation of physiological signals has been left up
to clinicians and researchers. For example, a physician will check vital signs, evalu-
ating the values collectively and assessing the physiology based on his/her knowledge
and experience. Such processing could be based on understanding of human physiol-
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Figure 5-5: Signal abnormality in blue and physical activity in red. In general the
quality of the signal degrades when the activity increases, but it can be seen that
around 4700 s, corresponding to running on the treadmill the second time, the quality
was poorer than the first first time running on the treadmill, which started around
2000 s, even though the activity levels are comparable.
ogy or simply pattern recognition. When working with a few values, this approach is
efficient and tractable. When complexity reaches a certain point, however, it becomes
too much for the mind to store and process. For example, physicians examine data
instantaneously or in short stretches, but looking at an entire day or week of heart
rate would not be practical. It has also been suggested that the mind can only process
four variables at one time [78]. As data sets get larger and higher in dimensionality,
it is increasingly less tractable for a clinician to process the information. There is
much information in the relationships among the signals that is subtle. The num-
ber of relationships between variables is proportional to the square of the number of
variables. It is only practical therefore that computers find more of the patterns and
relationships among physiological variables.
From our data we had 8 signals: ECG on 2 devices, ABP, PPG, respiration, and
3 axes of acceleration. From these signals were derived several other values such as
heart rate and respiration rate, as well as estimated values like CO, TPR, and PA.
CO and TPR are a mix of information regarding heart rate and blood pressure. Our
activity measure is a fusion of all 3 axes for a simpler representation. Plotting CO
and PA together gives a good idea of how the heart is responding to an increased
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workload. TPR and PA together give a good idea of how the vasculature responds
to an increased workload. We reduced our data from several signals to two variables
that are meaningful to examine in the context of cardiac monitoring. Figures 5-6,
5-7, 5-8, and 5-9 show CO, TPR, and PA all plotted together for a variety of subjects.
The data was remarkably consistent, showing strong responses, especially to run-
ning and vigorous jumping. The healthiest individuals showed rapid increases in CO
and rapid decreases in TPR at the start of running. Most of the data was clear
enough for interpretation, though when the device started to break down, the quality
of the data was significantly reduced. The oldest subject showed slower dynamics;
this aspect bears further study, as it may provide insight into the state of cardiac
health of patients.
5.3.2 Redundancy
Many vital signs are not measured directly, but derived from other measurements. For
example, heart rate is derived from ECG or PPG signals by looking for the repeated
heart beat signatures and calculating HR based on the time interval between two
successive beats. Uncertainty and inaccuracies arise from noise in the measured signal
and from the algorithm utilized to extract features. Noise is typically mitigated by
hardware design improvements or filtering. Algorithms typically fail to accurately
detect a beat in the presence of noise. Failures include missed beats and misclassified
beats, resulting in a heart rate that is too fast or too slow. Thresholds can be used
to throw away outliers, but outliers can also be indications of real and problematic
physiology.
Accurate information is very important in the context of false alarm reduction.
Many alarms are based on thresholds that can easily be triggered by noise. One ap-
proach has been to increase the accuracy of algorithms, but there will always be noise
an algorithm cannot handle and there will be sensors that fail. Fusion of signals to
extract common information may reduce the need for further complicating algorithms
and the need to constantly check false alarms.
I explored some ways of using redundant information in the measurements to
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Figure 5-6: Subject 14865 was the oldest subject tested and showed a slower increase
in CO, possibly reflecting a more mature heart as well as a slower autonomic response.
The TPR also showed a slower response compared to the other subjects. Subject
11928 was a younger subject with quicker responses. The reason for the increases in
CO become clear with the context of activity.
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Figure 5-7: Subjects 14868 and 14869 show healthy responses, with rapid increases
in CO at the onset of running. It is also noted that their CO levels remain generally
higher during the second set of activities than during the first.
better estimate the calculated quantities. This approach works if noise in the different
signals is decoupled or uncorrelated. For heart rate, our data indicates that the
ECG and ABP noise are in fact sufficiently decoupled to allow improving accuracy
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Figure 5-8: Subjects 14673 and 14870 have similar features to those in Figure 5-7.
For subject 14673 the increase in PA during the jumping during the second set of
activities. There is a corresponding increase in CO as expected.
significantly. The assumption is that when the values of beat intervals from two
different sources differ greatly, one of the signals must be corrupted. In our case,
the more physiologically viable option is chosen. If the two are close, the average
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Figure 5-9: Subjects 14871 and 14874 exhibit noisier data than the previous subjects,
likely because they were the last subjects tested and the device had degraded. The
general responses are similar, but there are very noisy stretches. This ties into the
discussion of when it is possible to trust data.
of the two is taken as the best estimate. This approach will fail only when the two
signals deviate in the same way, in which case nothing can be done by this approach
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to improve the signal. If both deviate, but by different amounts, we take the best
of the two. One advantage of this approach with heart rate is that there are several
physiological measurements from which it can be derived, so the accuracy will be
improved with more signals such as ABP, PPG, and multiple leads of ECG if their
noise sources are independent. Another example of redundancy could be improving
our TPR estimate by looking at the pulse wave reflection in the ABP and PPG.
This approach is not new, but needs to be explored further and needs to find
a greater clinical presence [76]. Similar models have been demonstrated in clinical
settings, but we demonstrate it in an ambulatory setting where the need to mitigate
noise is greater [79]. Figure 5-10 shows two examples of heart rate derived from ECG
and ABP and heart rate estimated from the two signals.
5.3.3 Activity Triggered Snapshots
One major advantage of having accelerometer data is the context it provides for
physiological changes. If an individual is wearing an ECG monitor and an HR spike is
detected, it could be because of fear or exercise - those are two different physiological,
despite some common manifestations. Similarly a sudden drop in blood pressure
might be a concern, but not if it is known the person has just lain down. There is
increasing interest in extracting information such as body position, activity level and
adverse events such as falling from accelerometers [80]. As algorithms improve for
such detection, information will be more accurate regarding movement of the body.
We looked at two different events and the accompanying physiology, one being
the transition from supine position to being upright, and the other being recovery
from activity. The first event is detected when the z-axis transitions from around 1
G for a period of time to 0 G and the y-axis transitions from 0 G to 1 G for a period
of time. The corresponding physiological changes are plotted with enough time to
see return to a steady state. If a person wore the device for a week, data would be
recorder every day they got out of bed. The second event is detected when average
activity level is above a certain threshold for a given time and transitions to below a
lower threshold for another period of time. An example of such detection is seen in
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Figure 5-10: The plots above show heart rate derived from ECG (blue) and ABP
(black). Many deviations are seen where the heart rate suddenly drops or spikes.
The bottom plots show the heart rate as estimated from the above data. Most of the
large deviations have been removed. It is noted that two heart rate drops remain,
around 1700 s and 4300 s. These are associated with Valsalva maneuvers and are
in fact physiologic. A simple thresholding method would likely have removed these
important data points.
Figure 5-11. The detection algorithm used is very basic, but worked well on the rest
of the subjects. Figure 5-12 shows data from the first time arising from the supine
position and data from recovery after exercise. ABP, CO and TPR waveforms are
shown. As mentioned previously, an advantage of this approach is that snapshots
that are useful distillations of the raw data can be presented to a clinician, to save
time sifting through data or to save power by selective data transmission.
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Figure 5-11: The PA is shown in red as has been displayed previously. The regions
in time corresponding to getting up from a supine position (cyan) and recovery from
exercise (black) are marked.
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Figure 5-12: The plots above correspond to arising from a supine position and the
plots below correspond to recovery from exercise. The plots on the left show ABP
waveforms and the plots on the right show CO (blue) and TPR (green). These
short data stretches (three minutes) provide key information that can be detected
automatically as opposed to providing a clinician with an entire data set.
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Chapter 6
Discussion and Outlook
6.1 Clinical Relevance
Up to this point wearable sensors have not made their way into everyday medicine, but
have vast potential. We have presented results showing the possibility of estimating
important quantities such as CO, TPR, and PA from data collected with wearable and
portable sensors. Though not free of noise, the data shows clear patterns that can be
explained by the underlying cardiovascular physiology. By using known physiology,
we leverage the data we collect from wearable sensors and produce estimates that can
be clinically relevant. We recognize the need for further development in several areas
of this research.
With wearable devices being deployed in everyday settings and collecting large
volumes of data, the paradigm for diagnostic and monitoring medical sensors will
necessarily shift. It will be critical to present clean data to end-users, or at least
methods for locating clean portions of data, as we have described. It is very likely
that interpretation of such data will be based on established knowledge and validated
models as opposed to pattern recognition and statistical methods alone. We be-
lieve that various cardiovascular conditions will be manifest in the estimates we have
described. From a devices perspective, it is not unreasonable to think that future
wearable sensors will include ECG, acceleration and ABP.
In research settings, many heart health scores have been proposed for risk strati-
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fication. Examples include maximum exercise capacity, heart rate variability (HRV),
heart rate recovery (HRR), and morphological variability [81, 82, 83, 84]. Significant
correlations with mortality have been demonstrated in these cases, but the underly-
ing mechanisms are generally still not well understood. The prevailing theory is that
HRV and HRR can be used to estimate the performance of the autonomic response
system [85]. Though HRV has been studied for decades and has promise, it has not
found its way into the clinic. By reporting to physicians quantities that they are fa-
miliar working with, we increase the likelihood that they incorporate the information
into their practice.
This approach is particularly attractive because it is not clinically disruptive. It
is very difficult to change established practice in medicine; by introducing radical
changes that disrupt work flow or add overhead in terms of money and time to the
physician, they are much less likely to be adopted. We report quantities that are
intuitive for physicians and can be absorbed quickly, using plots such as those we
have shown.
Future work with this data will continue to focus on reducing the dimensionality
of the data to provide clinically relevant information. It is also recognized that the
data set used is limited in size, and larger data sets will be necessary to properly
analyze these techniques.
6.2 Usage Models
Several usage models have been put forth, and we would like to clarify where we see
the potential for impact. Principles of usage include minimal physician interaction,
minimal data for a physician to review, and maximum positive predictive value. Home
monitoring of those with heart conditions or those over a certain age would be ideal
if the devices were cost-effective and easy to use. By doing a test over several days
once a year, the physician could gather some statistics on the patient's cardiac health.
This would allow the physician to notice any changes from baseline over time. This
usage model would require some scores for evaluating CO and TPR during exercise,
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standing up or similar routine activities. Providing physicians with a few scores and
plots would allow them to easily track patients from year to year to notice any change.
Another usage model would be for continuous monitoring such as in nursing homes.
If a patient who was at high risk for an acute adverse heart event could continually
wear a monitor, progress could be monitored on a time scale of weeks to watch for
any warning signs. Research in this area is just starting, as extended wear sensors
are being made more generally available.
A related area might be monitoring of low-risk hospital patients during their stay.
Currently high risk patients can be relocated to the ICU where they are intensely
monitored. Lower-risk patients might wear a pulse oximeter and have their vital
signs taken on a schedule, but with inexpensive wearable monitors that process data
in real-time, it might be easier to simply put one on every patient.
Another application space that has not been explored very much is world health.
This application is particularly interesting because of the constraints of limited physi-
cians and battery power. It would therefore be very useful to collect data in a portable
setting, do some pre-processing, and transmit important information to a remote
physician who could then make an assessment to be transmitted back. The biggest
challenge may be that the market will have a hard time driving such a technology in
a resource-poor setting.
6.3 To Device Makers
Through the experience of collecting data we were able to provide some feedback
to the makers of the prototype device, and this can be generalized to a broader
wearable medical device set of applications. The single most important factor when
human testing is in the development loop is to do everything possible to shorten
the development cycle. This has application to the development of the device, the
protocol or the data analysis. Decreasing the feedback time dramatically decreases
the development time. For example, when it took a long time to get data from the
device, it was very hard to modify our protocol to get the cleanest data. When the
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delay is reduced, the optimization can converge quickly and be useful. Time is also
one of the huge advantages of on-board processing. When the processed data can be
examined quickly, modifications can be made quickly to converge on solutions.
Another item is to have a set of usage models in mind to help drive testing. It is
also extremely important to think about how well a device and data will be received
by the medical community. A device will make no difference if it does not make it
into the clinic; it must be attractive for adoption by clinicians.
6.4 To Clinicians
By participating in the development process we came to appreciate some of the chal-
lenges in developing such a device. First, it takes time to develop a device, and
physicians would like things to get to them sooner. We are also aware that physicians
time is very constrained and valuable. Given these constraints, I believe the key is
that device makers need real feedback, not just what they think physicians will want.
Having collected some data and represented it, this should give a flavor of the idea
of what can be done. Clinicians need to be willing to test new devices and provide
feedback. Collaboration with designers is key.
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COUHES Forms
A.1 Application
Mamsacusetts Institute of Application # 09090034
Technology (assigned by 36
Committee on the Use of COUHES)
Humans as Experimental Subjects Date 09/18/09
APPLICATION FOR APPROVAL TO USE HUMANS AS EXPERIMENTAL
SUBJECTS (STANDARD FORM)
Please answer every question. Positive answers should be amplifled with details. You must mark N/A where
the question does not pertain to your application. Any incomplete application will be rejected and returned
for completion. A completed CHECKLISTFOR STANDARD APPLICATION FORM must accompany
this application.
1 BASIC INFORMATION
L Title of Stidy
Evaluation of a Wearable Wireless Cardiac Monitor
2. Principal nvestigator
Name: George C. Verghese Building and Room #: 10-140K
Title: Professor of Electrical Engineering Email: verghese@mit.edu
Depaotment EECS Phone: 617-2534212
3. Study Personnel
All key personnel' including the PI must be listed below, with a brief statement of
qualifications and study role(s).
Important Note: all key personnel are required to complete Human Subject training
before work begins on the pr 'ecr.
Investigators and other Qualificatfons: Describe Study role(s): (Check
personnel (and briefly box to the right if
institution(s)]: person will be
obtaining consent.)
George Verghese, PhD Signal processing, control Principal investigator
theory
Thomas Heldt, PhD Medical engineering, Principal study
signal processing, study coordinator
design _________
see Attachment I for list of d g
further study personnel
4. Collaborating Institutions. If you are collaborating with anoiter nstitution(s) then you must
obtain approval from that instituton's institutional review board, andforward copies ofthe approval to
COUHES)
None
'MIT key personnel all individuals who contribute in a substantive way to the execution ad rnonitoring of
the study at or on behalf of MIT or affiliated institutions. Typically, these individuals have doctoral or other
professional degrees. although other individuals may be included. In particular. investigators and staff
involved in obtaining informed consent are considered key personnel.
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5. Location of Research. If at MIT please indicate where on campus. If you plan to use the facilities
of the Clinical Research Center you will need to obtain the approval of the CRC Advisory Committee. You
may use this formfor simultaneous submission to the CRC Advisory Committee.
MIT General Clinical Research Center
6. Funding. If the research isffunded by an outside sponsor, please enclose one copy of the research
proposal with your application. A draft of the research proposal is acceptable.
A. Type of funding: B. Source of funding
n Contract/Grant [ Federal Government
F]Subcontract []Other Gov. (e.g. State, local)
LI Departmental Z Industry
Gift Other Private
SOther: Departmental Funds
[]No Funding []Other:
Have funds been awarded? Specify name of source designated above:Texas
Z Yes Pending No Instruments
Award #, if known
C. If Contract of Grant
Name of Contract or Grant: Contract or Grant Title:
Contract or Grant Number: OSP#: 2742062
7. Human Subjects Training. All study personnel MUST take and pass a training course on
human subjects research. MIT has a web-based course that can be accessedfrom the main menu of the
COUHES web site. COUHES may accept proof of training from some other institutions. List the names of
all study personnel and indicate if they have taken a human subjects training course.
George Verghese (human subjects test most recently renewed on 03/11/2009)
Thomas Heldt (human subjects test most recently renewed on 03/09/2009)
Faisal Kashif (human subjects test most recently taken on 12/10/2007)
Varun Chirravuri (human subjects test most recently taken on 02/03/2009)
8. Anticipated Dates of Research
Start Date: November 2009 Completion Date: November 2010
I. STUDY INFORMATION
1. Purpose of Study. Please provide a concise statement of the background, nature and reasons for the
proposed study. Use non-technical language that can be understood by non-scientist members of COUHES.
By 2020, the number of people in the United States above the age of 65 is projected to
grow by 44%, as about 80 million baby-boomers will have reached retirement age by
then. Health-care budgets therefore grow to take up a larger and larger fraction of gross
domestic product as individuals in that age bracket contribute disproportionately to
health-care cost. Furthermore, it is obvious that the number of health-care providers
cannot increase in proportion to the number of elderly. (In fact, the U.S. is already facing
a shortage of nurses that is projected to reach over 1 million full-time nurses, or 38% of
the projected demand, by 2020.) Consequently, there is a very strong need for improved
monitoring of chronic disease conditions outside of expensive, high-acuity health-care
environments (hospitals in particular), and also for improved health surveillance to
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prevent the most catastrophic - and therefore costly - medical conditions and emergencies
(such as, for example, heart attacks) from occurring.
The confluence of wireless, non-invasive, miniaturized, low-power sensor technology
and ubiquitous low-cost wireless communication channels (cell phones, local-area
networks) will enable the continuous acquisition, processing, and streaming of important
vital-sign information for improved health monitoring inside and outside traditional
health-care environments. Currently, few such vital-sign monitors exist that allow for
recording of physiological information for periods of greater than 24 to 48 hours.
This study aims to characterize the performance of a prototype wearable wireless cardiac
monitor that has the capability to record electrocardiographic and accelerometer data for
up two weeks at a time without the need to exchange batteries or download the acquired
data. In particular, this study aims to collect ECG and motion information from such a
prototype while simultaneously recording vital-sign information using clinically
approved medical devices. In this study, we focus on collecting data from healthy, adult
volunteers during many physical maneuvers (resting recumbently, sitting, standing up,
standing quietly, walking, light jogging, light jumping, arm reaching, simulated stair-
stepping) commonly encountered during regular life. We will evaluate the performane of
the prototype monitor against the data collected simultaneously from the approved
clinical devices. Discrepancies in data quality will help drive improvements to the
prototype design.
2. Study Protocol. For biomedical, engineering and related research, please provide an outline of
the actual experiments to be performed. Where applicable, provide a detailed description of the
experimental devices orprocedures to be used, detailed information on the exact dosages of drugs or
chemicals to be used, total quantity of blood samples to be used, and descriptions of special diets.
For applications in the social sciences, management and other non-biomedical disciplines
please provide a detailed description of your proposed study. Where applicable, include copies of any
questionnaires or standardized tests you plan to incorporate into your study. Ifyour study involves
interviews please submit an outline indicating the types of questions you will include.
You should provide sufficient information for effective review by non-scientist members of
COUHES. Define all abbreviations and use simple words. Unless justification is provided this part ofthe
application must not exceed 5 pages.
Attaching sections of a grant application is not an acceptable substitute.
Before interested individuals are invited to an experimental session, they will be briefed
on the background and scope of the study, on disqualifying medical conditions, and on
the experimental protocol. Subjects will also be briefed on the prototype wearable
wireless cardiac monitor and on the other medical instrumentation involved in the study.
On the day of the experimental session, informed consent will be obtained and the subject
will be asked to provide basic personal information, such as gender, age, body height,
body weight, race, and ethnicity. Furthermore, the subjects will be asked to fill out a
basic health-history questionnaire. Furthermore, the subject's resting heart rate,
respiratory rate, and arterial blood pressure will be measured prior to instrumentation.
The subject will then be instrumented, which consists of attaching the prototype wearable
wireless cardiac monitor to his/her chest using standard medical electrocardiogram
(ECG) electrodes, and applying a second set of three ECG electrodes for measuring the
ECG with a clinical electrocardiograph. Furthermore, a motion sensor (accelerometer)
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and a temperature sensor will be affixed to the subject's chest, using standard medical
tape. A pulse oximeter probe will be placed on a digit of the left hand, while pressure
cuffs will be placed on the third and fourth digits of the right hand. Finally, elastic bands
will be placed around the subject's chest and abdomen, respectively, to measure
respiratory chest and abdominal wall excursions. Cables of the clinical ECG monitor, the
arterial blood pressure monitor (Portapres), and the pulse oximeter will be affixed to a
belt around the subject's waist to minimize the potential for the subject to trip or for the
sensors to be torn off.
The study commences with the subject resting comfortably in the supine position on a
bed or a medical-examination table for five minutes while baseline data is being
collected. At the conclusion of the five-minute period, the subject is asked to get up from
the recumbent position and to sit quietly on a chair for five minutes. (Given the level of
instrumentation, it might be difficult for the subject to get up alone; the study personnel
will aid in the process if/when necessary.) After the five-minute period in the seated
position, the subject will be asked to get up and to stand quietly for five minutes. The
subject will be allowed to contract his/her calf musles or to gently step
forwards/backwards or sideways if that improves comfort during the standing period.
After the five-minute standing period, the subject is asked to hop lightly in place (light
jumping) for up to one minute (the toes need not to lift off the ground). At the conclusion
of the hopping period, the subject is asked to make horizontal in-plane movements with
his/her left arm to engage the left pectoralis muscle (simulation of muscle noise in the
ECG) for one minute. At the conclusion of the arm movement exercise, the subject will
be asked to perform a 10-second Valsalva (straining) maneuver. At the conclusion of the
Valsalva maneuver, the subject will be asked to step onto a treadmill and to walk
comfortably (at speeds no greater than four miles/hour) for up to five minutes. At the
conclusion of the walking period, the speed of the treadmill will be increased slowly until
the subject jogs lightly and comfortably (at speeds no greater than seven miles/hour) for
up to five minutes. At the conclusion of the five-minute period of light jogging, the speed
of the treadmill is slowly reduced until the treadmill belt comes to a complete standstill.
The subject will then be asked to stand behind the rear end of the treadmill and perform a
simulated stepping exercise by repeatedly stepping onto the stopped treadmill and back
down again. This exercise will last up to one minute.
This sequence of events will take approximately 30 minutes and will be repeated once for
a total study duration of about one hour. The start and end of each intervention will be
marked on the electronic data acquisition system with the help of an event marker.
At the conclusion of the final intervention, the study staff will remove the instrumentation
and will give the subject the chance to freshen up. Finally, the subject will be asked to fill
out an exit questionnaire before the experimental session concludes.
3. Drugs and Devices. If the study involves the administration of an investigational drug that is not
approved by the Food and Drug Administration (FDA)for the use outlined in the protocol, then the principal
investigator (or sponsor) must obtain an Investigational New Drug (IND) numberfrom the FDA. If the study
involves the use of an approved drug in an unapproved way the investigator (or sponsor) must submit an
application for an IND number. Please attach a copy of the IND approval (new drug), or application (new
use.).
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If the study involves the use of an investigational medical device and COUHES determines the device poses
significant risk to human subjects, the investigator (or sponsor) must obtain an Investigational Device and
Equipment (IDE) number from the FDA.
Will drugs or biological agents requiring an IND be used? YES NON
If yes, please provide details:
Will an investigational medical device be used? YESM NOE]
Ifyes, please provide details: see Attachment II to this document.
4. Radiation If the study uses radiation or radioactive materials it may also have to be approved by
the Committee on Radiation Exposure to Human Subjects (CORE HS). COUHES will determine if you need
COREHS approval
Will radiation or radioactive materials be used? YESLI NO2
If yes, please provide details:
5. Diets
Will special diets be used? YES[] NOZ
If yes, please provide details:
IIL. HUMAN SUBJECTS
1. Subjects
A. Estimated number: 15 B. Age(s): > 18; < 65
C. Inclusion/exclusion criteria
i. What are the criteria for inclusion or exclusion?
Exclusion criteria: known diagnosis or history of cardiovascular diseases
(implanted cardiac pacemaker or difibrillator, hypotension or hypertension,
coronary vascular disease, varicose veins, congestive heart failure, cardiac rhythm
disturbances, or any medication for such conditions); history of fainting or
postural hypotension; low exercise tolerance or history of shortness of breath;
autonomic neurophathy; diabetes mellitus; use of alcohol, sedatives, or
recreational drugs within 24 hours of participation; pregnancy; having slept less
than six hours the night prior to participation or having slept less than 18 hours
over the course of the three days prior to participation; skin sensitivity to medical
adhesives (tape, electrodes) or electrode gels; history of balance problems; known
diagnosis or history of respiratory disease; age less than 18 years.
ii. Are any inclusion or exclusion criteria based on age, gender, or
race/ethnic origin? If so, please explain and justify
Yes. Exclusion criteria apply for persons under the age of 18 as the focus of our
investigation is primarily on health surveillance for the adult population in this first
feasibility study of the device. On the recommendation of the Scientific Advisory
Committee of MIT's Clinical Research Center, we limit the upper age of participation to
65 years.
D. Please explain the inclusion of any vulnerable population (e.g. children,
cognitively impaired persons, non-English speakers, MIT students), and why that
population is being studied.
Many MIT students are healthy young adults, so we will include students in our study.
2. Subject recruitment Identification and recruitment of subjects must be ethically and legally
acceptable and free of coercion. Describe below what methods will be used to identify and recruit subjects
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Recruitment to this study will be done primarily through the use of flyers but also
through the word of mouth.
Please attach a copy of any advertisements/ notices and letters to potential subjects
3. Subject compensation Payment must be reasonable in relation to the time and trouble associated
with participating in the study. It cannot constitute an undue inducement to participate
Describe all plans to pay subjects in cash or other form of payment (i.e. gift
certificate)
There will be no compensation (cash, gift certificate, or other) for participation in this
study.
Will subjects be reimbursed for travel and expenses?
No.
4. Potential risks. A risk is a potential harm that a reasonable person would consider important in
deciding whether to participate in research. Risks can be categorized as physical, psychological,
sociological, economic and legal, and include pain, stress, invasion ofprivacy, embarrassment or exposure
of sensitive or confidential data. All potential risks and discomforts must be minimized to the greatest extent
possible by using e.g. appropriate monitoring, safety devices and withdrawal of a subject if there is evidence
of a specific adverse event.
What are the risks / discomforts associated with each intervention or procedure in
the study?
Instrumentation:
The Portapres device measures arterial blood pressure through the volume-clamp method,
which applies a continuous, time-varying pressure to the finger at which arterial pressure
is to be measured. While the device is especially designed for long-term blood pressure
measurement, some people might consider this measurement uncomfortable.
Furthermore, the subject will be instrumented with an electrocardiograph, an
accelerometer, a pulse-oximeter, and an experimental medical device (our wearable,
wireless cardiac monitor). In general, any electrical device connected to a subject poses
the risk of electric shock.
Interventions:
The protocol includes quiet standing, walking and light jogging on a treadmill, as well as
simulated stair stepping, and light jumping. Quiet standing might induce pre-syncope and
syncope in some subjects. Walking and light jogging on a treadmill might pose the risk of
exertion and falling off the treadmill. Finally, some subjects might consider simulated
stair stepping and light jumping to be uncomfortable, especially if performed over longer
periods of time.
What procedures will be in place to prevent / minimize potential risks or
discomfort?
Instrumentation:
The Portapres device allows for switching of blood pressure measurements between two
fingers to rest one finger while the device records pressure from a neighboring finger.
This will reduce the level of discomfort experienced by the subject. The Portapres,
electrocardiograph, and pulse oximeter are approved medical devices and therefore
adhere to FDA electrical patient-safety standards. The accelerometer sensor does not
directly measure bioelectric potentials or currents from the patient's body; it is therefore
electrically isolated from the patient and poses no risk for electric shocks. The prototype
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cardiac monitor is a low-power, low-voltage electronic device that poses minimal thermal
or electric risk to the subject.
Interventions:
During the quiet standing phases of the protocol, study subjects will be encouraged to
activate the muscle pumps in their calves by either shifting their weight from one leg to
the other and back or by taking small steps back and forth. During the study, heart rate
and blood pressure are monitored continuously. The experiment will be terminated
immediately if heart rate rises excessively or drops precipitously (vasovagal syncope) or
blood pressure drops noticably. (No hard thresholds can be given as our experience with
prior clinical studies has shown that normal, healthy study subjects can present with a
wide range of baseline heart rates and arterial blood pressures.) Furthermore, the study
will be terminated immediately if the subject reports any signs or symptoms of pre-
syncope (dizziness, blurred vision, shrinking of peripheral vision, sense of impending
loss of consciousness).
While the study subject is on the treadmill during the walking and light jogging phases of
the protocol, one member of the study staff will be standing behind the treadmill to catch
the subject should he/she roll off the treadmill. Walking and light jogging will be limited
to up to five minutes, while simulated stepping and light jumping will be limited to up to
one minute each.
At the end (and if necessary at any earlier point of the sequence of interventions),
subjects will be given the opportunity to rest, recover, and rehydrate.
The study will be performed at MIT's Clinical Research Center (CRC), and the nurse
assigned to the study will provide assistence throughout the study protocol, which adds
another layer of safety.
5. Potential benefits
What potential benefits may subjects receive from participating in the study?
Subjects will receive no direct benefits from participating in this study. However, subjects
will be informed about any abnormal finding, such as arrhythmias, that might be detected
during the study or during retrospective review of the data. In such cases, the data will be
made available to the subject's physician for review and assessment, at the subject's
request.
What potential benefits can society expect from the study?
The potential benefit to society derives from an in-depth evaluation of the wearable
wireless cardiac monitor and the associated improvements in monitor design.
6. Data collection, storage, and confidentiality
How will data be collected?
Data will be collected (1) on paper, (2) by a dedicated data-acquisition system, and (3) on
the prototype cardiac monitor. The data collection devices are all non-invasive (no
penetration of skin). Written data will be collected in form of a health questionnaire and an
exit questionnaire. Continuous physiological monitoring will be conducted using a single-
lead ECG monitor (Hewlett Packard 1500A Electrocardiograph); a non-invasive,
continuous blood pressure monitor (Finapres Medical Systems Portapres); a pulse oximetei
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(Criticare Systems 504-US); and a 3-d accelerometer (PCB Electronics). The resultant data
will be collected on a TEAC digital audio tape recorder. ECG and accelerometer data from
the wearable wireless health monitor will be acquired and stored on Flash memory directly
on the cardiac monitor for later retrieval by the study personnel.
Is there audio or videotaping? YES ] NO Explain the procedures you plan to follow.
Will data be associated with personal identifiers or will it be coded?
Personal identifiers[] Coded 0 Explain the procedures you plan to follow.
All research data collected during the experiment will be stored in de-identified electronic
files. The coding of each subject's data will prevent linking a subject's personal informatio
to the research data when it is analyzed or archived.
Where will the data be stored and how will it be secured?
All research data collected during this study will be stored in de-identified, electronic
format on computers. We plan to make the de-identified data available to the research
community through PhysioNet (www.physionet.org) or other such portals. The original
signed consent forms will be kept in a locked cabinet at the Principal Investigator's or
Study Coordinator's office.
What will happen to the data when the study is completed?
As outlined above, we plan to make the de-identified data available to the research
community.
Can data acquired in the study affect a subject's relationship with other individuals
(e.g. employee-supervisor, patient -physician, student-teacher, family relationships)?
The collected data cannot affect the subject's relationship with other individuals.
7. Deception Investigators must not exclude information from a subject that a reasonable person would
want to know in deciding whether to participate in a study.
Will information about the research purpose and design be withheld from subjects?
YES [] NON If so, explain and justify.
8. Adverse effects. Serious or unexpected adverse reactions or injuries must be reported to COUHES
within 48 hours. Other adverse events should be reported within 10 working days.
What follow-up efforts will be made to detect any harm to subjects and how will
COUHES be kept informed?
At the conclusion of the experiment, including the rest period, subjects will be asked to
ambulate around the examination room under the supervision of the study personnel. The
subjects will be asked whether they feel dizzy in the upright posture or have any other
cardiovascular symptoms. If subjects do not report any symptoms, they will be
discharged from the supervision of the study personnel. Subjects will be given the cell
phone number of the Principal Investigator and the Study Coordinator to report
immediately any symptoms of discomfort that might arise within 24 hours following the
study session. Any serious events will be reported by telephone to COUHES immediately
after such events are noticed or brought to the attention of the study personnel; a written
memo will be delivered to COUHES within 48 hours. Adverse events will be reported to
COUHES by e-mail within 10 days.
9. Informed consent. Documented informed consent must be obtained from all participants in studies
that involve human subjects. You must use the templates available on the COUHES web-site to prepare
these forms. Draft informed consent forms must be returned with this application. Under certain
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circumstances COUHES may waive the requirementfor informed consent.
Attach informed consent forms with this application.
10. The HIPAA Privacy Rule. If your study involves disclosing identifiable health information about
a subject outside of M.L T., then you must conform to the HIPAA Privacy Rule and complete the questions
below. Please refer to the HIPAA section, and to the definitions ofprotected health information, de-identifiec
data and limited data set on the COUHES web-site.
Do you plan to use or disclose identifiable health information outside M.I.T.?
YES [I NON
If YES, then the subject must complete an Authorization for Release of Protected Health Information Form.
Please attach a copy of this draft form. You must use the template available on the COUHES web-site.
Alternatively, COUHES may grant a Waiver of Authorization if the disclosure meets criteria outlined on
the COUHES web-site.
Are you requesting a Waiver of Authorization?
YES[J NON
If YES, explain and justify.
Will the health information you plan to use or disclose be de-identified?
YES NOFl
Will you be using or disclosing a limited data set?
YES E NO
If YES, then COUHES will send you a formal data use agreement that you must complete in order for your
application to be approved
IV. INVESTIGATOR'S ASSURANCE
I certify the information provided in this application is complete and correct
I understand that I have ultimate responsibility for the conduct of the study, the
ethical performance of the project, the protection of the rights and welfare of human
subjects, and strict adherence to any stipulations imposed by COUHES
I agree to comply with all MIT policies, as well all federal, state and local laws on the
protection of human subjects in research, including:
* ensuring all study personnel satisfactorily complete human subjects training
* performing the study according to the approved protocol
* implementing no.changes in the approved study without COUHES approval
* obtaining informed consent from subjects using only the currently approved
consent form
* protecting identifiable health information in accord with the HIPAA Privacy
Rule
* promptly reporting significant or untoward adverse effects
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Signature of Principal Investigator
Print Full Name and Title
Signature of Department Head Date
Print Full Name and Title
Please return 3 hard copies of this application (1 with original signatures) to the
COUHES office E25-143b.
APPLICATION FOR APPROVAL TO USE HUMANS AS EXPERIMENTAL SUBJECTS
(STANDARD FORM) - revised 6/2/2009)
-10-
137
Date
A.2 Recruitment Flyer
Recruiting Volunteers for
Human-Subjects Study
We are recruiting volunteers for a human-
subjects study, evaluating the
performance of a novel wearable wireless
cardiac monitor.
If you are interested, please contact
thomas@mit.edu, 617-324-5005.
Cardiac monitor study
thomascmit.edu
617-324-5005
Cardiac monitor study
th omasgmit.edu
617-324-5005
Cardiac monitor study
thomas@mit.edu
617-324-5005
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CRC PROTOCOL #:608
COUHES PROTocOL #:
CONSENT FORM, WEARABLE WIRELESS CARDIAC MONITOR 1/7
CONSENT TO PARTICIPATE IN BIOMEDICAL RESEARCH
Eval uati on of a wearabl e i rel ss
cardiac Monitor
You are asked to participate in a research study conducted by George Verghese, PhD,
Thomas Heldt, PhD, and their students from the Research Laboratory of Electronics at
the Massachusetts Institute of Technology. The results of this study may be published in
de-identified form in a student thesis or scientific journal, and will be made available
freely to the scientific community. You have been asked to participate in this study
because you have volunteered and - based on the information you have provided - meet
the minimum health and physical requirements for our study. You should read the
information below carefully, and ask questions about anything you do not understand,
before deciding whether or not to participate.
PARTICIPATION AND WITHDRAWAL
Your participation in this research is completely VOLUNTARY. If you choose to
participate you may subsequently withdraw from the study at any time without penalty or
consequences of any kind. The investigator may withdraw you from this research if
circumstances arise that warrant doing so. Such circumstances include the emergence of
evidence that you do not in fact meet the minimum health and physical requirements, or
that during the study it becomes clear to the experimenter that you are becoming fatigued.
If you choose to not participate or to withdraw at any point, it will not affect your
relationship with M.I.T. or your right to health care or other services to which you are
otherwise entitled.
You should not participate in this study if your answer to one or more of the following
questions is "yes":
" Do you have a diagnosed heart or vascular condition? This could be a coronary heart
disease, varicose veins, cardiac arrhythmias, congestive heart failure.
" Do you have an implanted cardiac pacemaker or defibrillator?
* Do you suffer from cardiac arrhythmias?
" Do you have a history of fainting, dizziness or low blood pressure upon standing up?
" Do you have skin sensitivity to medical adhesives (tape, electrodes) or electrode gels?
" Do you have a medical respiratory condition?
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" Are you are under the influence of alcohol, sedatives, or recreational drugs, or have
you consumed alcohol or taken sedatives or recreational drugs in the past 24 hours?
e Is there the possibility that you might be pregnant?
* Do you have diabetes?
" Do you suffer from poor sensation in your legs or other neurological deficits?
" Do you have low exercise tolerance or develop shortness of breath easily?
" Have you slept less than 6 hours last night, or have you slept less than 18 hours in
total in the last three days?
PURPOSE OF THE STUDY
The purpose of the research is to investigate the performance of a novel prototype
wearable wireless cardiac monitor.
PROCEDURES USED IN THIS STUDY
If you agree to participate in this study, we would ask you to consent to the following:
" You will be asked to provide basic personal information such as age, gender,
body height, body weight, race, and ethnicity.
* You will be asked to provide basic information about your current state of health
and your health history.
" Prior to commencing the experimental protocol, the experimenters will take your
heart rate, blood pressure, and respiratory rate, using standard clinical methods.
" Six non-invasive electrodes will be placed on the surface of the skin on your
chest.
* Three of these electrodes will be attached to the wearable wireless cardiac
monitor.
* The remaining three electrodes will be connected to a standard
electrocardiograph.
* A non-invasive temperature probe will be placed on your skin.
* Non-invasive blood pressure cuffs will be placed on two of your fingers.
* A non-invasive sensor for your blood oxygen levels will be placed on one of your
fingers.
* A small motion sensor will be affixed to your chest.
* During the experimental session, you might be asked several questions relating to
your general sensation or questions about your well-being.
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* During the experimental session, you will be asked to
o rest in the horizontal position for five minutes,
o sit on a chair for five minutes,
o stand for five minutes,
o hop lightly in place for up to one minute,
o move your left arm in a horizontal plane for one minute,
o perform a brief straining maneuver,
o walk on a treadmill at a comfortable speed for five minutes,
o jog lightly on a treadmill at a comfortable speed for five minutes, and
o step onto and off the stopped treadmill repeatedly for up to one minute.
" You will be asked to perform the entire cycle of interventions described above
twice, possibly with rest in between.
* You might be asked to answer a series of questions at the end of the experimental
session.
The total time for participation will be 2 hours at most.
You may terminate the experiment at any time
by telling the experimenter you wish to stop.
POTENTIAL RISKS AND DISCOMFORTS
During the experiment you may experience one or more of the following:
* A pressure sensation at the finger at which your blood pressure is being
measured. We can minimize potential discomfort by alternating the blood
pressure measurement between two fingers.
* Skin irritation at the sites of electrode application.
* Electrical shocks. The electrical devices to which you will be attached pose
minimal risk of electrical shocks as they are either designed for clinical use
and therefore adhere to stringent electrical safety standards or are of such low
electrical voltage and power that they don't pose a risk.
Further discomfort might be experienced during the following interventions:
* Quiet standing:
Some people experience dizziness or the feeling of impending loss of
consciousness during quiet standing. We minimize this risk by limiting quiet
standing to five minutes at a time and by allowing you to contract your calf
muscles, by shifting your weight from one leg to the other, or by gently stepping
forward/backwards or sideways. We will also be monitoring your heart rate and
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arterial blood pressure continuously for any signs of abnormality.
* Light hopping/jumping:
Some people might find light jumping inconvenient. We limit the time for this
intervention to one minute and allow for vertical bouncing in which the toes need
not lift off the ground.
" Walking/light jogging:
Depending on your exercise tolerance, you might experience an increase in heart
rate and sweating while walking or jogging on the treadmill. Furthermore, you
might be at risk of falling off the treadmill. We will limit the treadmill's speed to
your comfort level for both the walking and light-jogging phase of the protocol. In
any case, the speed will not exceed 4 miles/hour for the walking phase and 7
miles/hour for the light-jogging phase of the protocol. Furthermore, each of the
two phases is limited to five minutes. You will be protected from falling of the
treadmill by side rails and by members of the study staff who will be standing
behind the treadmill to catch you in case you should trip.
* Simulated stair stepping:
Some people might feel discomfort in stepping repeatedly onto and off the
treadmill. We limit the time for this phase of the protocol to one minute to
minimize such potential discomfort.
Members of the study staff will frequently ask you about your well-being to ensure your
comfort, and will monitor your alertness through communication. You will be
continuously monitored by at least two experimenters in the room.
The procedures may involve risks that are currently unforeseeable.
ANTICIPATED BENEFITS TO SUBJECTS
You will receive no benefits from this research.
ANTICIPATED BENEFITS TO SOCIETY
The potential benefits to science and society are a better understanding and possibly an
improved design of a wearable wireless cardiac monitor. This in turn may provide
improved health care for home-bound and high-risk patients.
PAYMENT FOR PARTICIPATION
You will receive no compensation for your participation in this study.
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FINANCIAL OBLIGATION
Neither you nor your health insurance will be billed for your participation in this study.
PRIVACY AND CONFIDENTIALITY
The members of the research team and, if appropriate and requested by you, your
physician and nurses are the only people who will know that you are a research subject.
No information about you, or identifiable information provided by you during the
research will be disclosed to others without your written permission, except if necessary
to protect your rights or welfare, or if required by law.
After the experiment, all data and information collected during the experiment will be
stored in an electronic database in de-identified format, which means that it will be
impossible to trace the stored data and information back to you. We will make the de-
identified data collected from this study freely available to the research community at
large. This might involve posting data on Internet portals such as PhysioNet
(www.physionet.org). When the results of the research are published or discussed in
conferences, no information will be included that would reveal your identity.
WITHDRAWAL OF PARTICIPATION BY THE INVESTIGATOR
The investigator may withdraw you from participating in this research if circumstances
arise which warrant doing so. If you experience abnormally high heart rate, low blood
pressure, drowsiness or dizziness, you may have to be discharged from the study, even if
you would like to continue. The investigators, George Verghese, PhD or Thomas Heldt,
PhD, will make this decision and will let you know if it is not possible for you to
continue. The decision may be made either to protect your health and safety, or because
it is part of the research plan that people who develop certain conditions may not
continue to participate.
NEW FINDINGS
During the course of the study, you will be informed of any significant new findings
(either good or bad), such as changes in the risks or benefits resulting from participation
in the research or new alternatives to participation that might cause you to change your
mind about continuing in the study. If new information is provided to you, your consent
to continue participating in this study will be re-obtained.
EMERGENCY CARE AND COMPENSATION FOR INJURY
If you feel you have suffered an injury, which may include emotional trauma, as a result
of participating in this study, please contact the person in charge of the study as soon as
possible.
In the event you suffer such an injury, M.I.T. may itself provide, or arrange for the
provision of, emergency transport or medical treatment, including emergency treatment
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and follow-up care, as needed, or reimbursement for such medical services. M.I.T. does
not provide any other form of compensation for injury. In any case, neither the offer to
provide medical assistance, nor the actual provision of medical services shall be
considered an admission of fault or acceptance of liability. Questions regarding this
policy may be directed to M.I.T.'s Insurance Office, (617) 253-2823. Your insurance
carrier may be billed for the cost of emergency transport or medical treatment, if such
services are determined not to be directly related to your participation in this study.
IDENTIFICATION OF INVESTIGATORS
In the event of a research related injury or if you experience an adverse reaction, please
immediately contact one of the investigators listed below. If you have any questions
about the research, please feel free to contact:
Principal Investigator: Co-Investigator:
George C. Verghese (10- 140K) Thomas Heldt (10-140L)
77 Massachusetts Avenue 77 Massachusetts Avenue
Cambridge, MA 02139 Cambridge, MA 02139
(617) 253-4612 (617) 324-5005
RIGHTS OF RESEARCH SUBJECTS
You are not waiving any legal claims, rights or remedies because of your participation in
this research study. If you feel you have been treated unfairly, or you have questions
regarding your rights as a research subject, you may contact the Chairman of the
Committee on the Use of Humans as Experimental Subjects, M.I.T., Room E32-335, 77
Massachusetts Ave, Cambridge, MA 02139, phone 1-617-253 6787.
SIGNATURE OF RESEARCH SUBJECT OR LEGAL REPRESENTATIVE
I have read (or someone has read to me) the information provided above. I have been
given an opportunity to ask questions and all of my questions have been answered to my
satisfaction. I have been given a copy of this form.
BY SIGNING THIS FORM, I WILLINGLY AGREE TO PARTICIPATE IN THE
RESEARCH IT DESCRIBES.
Name of Subject
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Name of Legal Representative (if applicable)
Signature of Subject or Legal Representative
7/7
Date
SIGNATURE OF INVESTIGATOR
I have explained the research to the subject or his/her legal representative and answered
all of his/her questions. I believe that he/she understands the information described in
this document and freely consents to participate.
Name of Investigator
Signature of Investigator Date (must be the same as subject's)
SIGNATURE OF WITNESS (If required by COUHES) I
My signature as witness certified that the subject or his/her legal representative signed
this consent form in my presence as his/her voluntary act and deed.
Name of Witness
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Signature of Witness Date (must be the same as subject's)
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A.4 Date Change
APPLICATION FOR CHANGES TO AN APPROVED PROTOCOL
Any change to a protocol that impacts human subjects must be approved by
COUHES. If the change is minor and involves no more than minimal risks to
subjects, an expedited review may be performed. All other changes are subject to a
full Committee review.
1. Titleof Study
Evaluation of a Wearable Wireless Cardiac Monitor
2. Investigator
Name: George C. Verghese Building and Room #: 10-140K
Title: Professor Email: verghese@mit.edu
Department: EECS Phone: 253-4612
3. Proposed Change. Please provide a detailed description of the proposed changes, and indicate how
these changes will affect the potential risks and benefits to the subjects. Define all abbreviations and use
simple words. Unless justification is provided, this part of the application must not exceed 2 pages. NOTE:
when adding study personnel state MIT or outside affiliation and include email address.
We propose changing the expiration date of the protocol from Oct. 14,2010 to Jan.
31,2011.
Please attach copies of all revised material (consent form, study protocol (PI & Dept.
Head signature required), recruitment, etc). Also, include a copy of all revised
material with changes HIGHLIGHTED. Any incomplete application will be rejected
and returned for completion.
Signature of Investigator
Signature of Dept. Head
Date
Date
Please submit a signed hard copy of this application including all revised material to the
COUHES office at E25-143b.
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XCHV Massachusetts Institute of Existing 09090034
Technology COUHES # 36
Committee on the Use of Date of last 10/15/200
Humans as Experimental Subjects approval 9
CONTINUING REVIEW QUESTIONNAIRE
Approval of your protocol by COUHES will, unless otherwise noted, expire one year
after the date of the last approval. Before extending its approval for an additional
period (usually one year) you must complete and return this form by the deadline
for the COUHES meeting that will be held before your expiration date (see dates
and deadlines: http://web.mitedu/committees/couhes/dates.shtml ). If this form is
not received by the required date, the study will be administratively closed and
research grants related to the study will be suspended. No further research with
human subjects can be conducted under this protocol.
Please answer every question. Positive answers should be amplified with details. You must mark N/A
where the question does not pertain to your application. Any incomplete application will be rejected and
returnedfor completion. Do not use thisform to request changes, attach an Application for Changes to an
Approved Protocolform. If you are not requesting renewal of this protocol, you should submit this form
to close the protocoL.
1. Title of Study
Evaluation of a Wearable Wireless Cardiac Monitor
2. Principal Investigator
Name: George C. Verghese Building and Room #: 10-140K
Title: Professor Email: verghese@mit.edu
Department: EECS Phone: 253-4612
3. Are you requesting renewal of COUHES approval for this project?
NO L YES F
4. Has there been a change in:
A. Responsible investigators? NO |_ YES M If yes, please explain: TWO
PREVIOUSLY APPROVED INVESTIGATORS (VARUN CHIRRAVURI AND
JERRY WANG) GRADUATED OR ENDED THEIR UROP IN OUR GROUP.
ALL study personnel includingfaculty, staff and student investigators, study coordinators, laboratory
technicians and assistants, must have taken and passed a training course on human subjects research.
ATTACH A LIST OF ALL PERSONNEL CURRENTLY WORKING ON THIS PROJECT TO THIS
FORM (include MIT or outside affiliation and email address).
NOTE: Human subjects training must be updated every 3 years.
B. Recruitment of subjects? NO YES [_ If yes, please explain:
C. Experimental procedure? NO YES ] If yes, please explain:
D. Experimental dnigs? NO 2 YES If yes, please explain:
E. Amount of blood drawn? NO YES If yes, please explain:
F. Amount of radiation exposure? NO x YES If yes, please explain:
G. Other aspects of the study that affect the rights of the subject?
NO H YES E If yes, please explain:
5. STUDY PROTOCOL: (provide an outline of the approved current research
CONTINUING REVIEW QUESTIONNAIRE- revised 8/10/2010
-1- ,
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protocol. You should provide sufficient information for effective review by non-
scientist members of COUHES. Define all abbreviations and use simple words.
Unless justification is provided, this part of the continuing review application must
not exceed 2 pages.)
CONTINUING REVIEW QUESTIONNAIRE- revised 8/10/2010
-2-
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Because of technical difficulties with the delicate wireless experimental ECG monitor,
we have fallen short of the recruitment target during the first year of study approval. We
would therefore like to keep the protocol open until we have recruited all 15 subjects
originally approved.
6. How many subjects have been studied?
Since the last approval: Since the start of the study:
CONTINUING REVIEW QUESTIONNAIRE- revised 8/10/2010
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Number of subjects approved for this study: 15
Number of subjects withdrawn from the study: (state reason for withdrawal, was Adverse
Event report submitted?): 0
7. Have your subjects experienced any adverse effects since the last approval? All
adverse effects must be reported to COUHES. If you have not reported an adverse event, please attach an
adverse event reporting form.
NO 0 YES[_|
8. Statement of Financial Interest
Have any of the financial interests of key personnel involved in the study changed since the last approval?
[Yes ZNo
If yes, and unless already submitted, please attach a Supplement for Disclosure of Financial Interest for
each change.
This supplement, together with detailed guidance on this subject and definitions of the highlighted terms, is
available on the COUHES web.
9. Funding. If the research is funded by an outside sponsor, the investigator's department head must
sign below. If not previously submitted, a copy of the research proposal is required ( a draft is acceptable).
A. Type of funding: B. Source of funding
[ Contract/Grant [] Federal Government
F Subcontract Other Gov. (e.g. State, local)
E]Departmental Industry
Z Gift Other Private
LI Other: []Departmental Funds
L No Funding LI Other:
Have funds been awarded? Specify name of source designated
0 Yes Pending No above:Toxas Instruments
Award #, if known
C. If Contract or Grant
Name of Contract or Grant: Contract or Grant Title:
Contract or Grant Number: OSP#:
10. Does your study require approal of any other committee (at or outside MIT)?
NO YESE] If yes, please attach current approval letters.
11. Have any results of the study been published?
NO Z YES LJ If yes, please provide bibliographic information.
12 Informed consent
Please attach a copy of the informed consent document you are currently using.
This should be the version most recently approved by COUHES.
If the requirement for informed consent has been waived by COUHES, please check this box L
Signature of Principal Investigator Date
Print Full Name
CONTINUING REVIEW QUESTIONNAIRE- revised 8/10/2010
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Signature of Department Head: Date
Print full name and title:_ Date
Please return a signed hard copy of this application to the COUHES office at
E25-143B.
CONTINUING REVIEW QUESTIONNAIRE- revised 8/10/2010
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Appendix B
Subject Record
. PAoOCO. : 60s
CoJHES PireCOL #-.0909003436
HEALTH HISTORY FORM, WEARABLE WIRELESS CARDIAC MONITOR ./3
Personal Information
Subject ID Number: .llk(
Age: 525 es Gender: Yn Race: Ethnicity: /0
Body weight: Body height: I3l z C
General Questions
I. How wouel you rate your general health?
Excellent B Good D Fair 17 Poor
2 What is your normal activity level?
D Almost no physical activity
B Mostly sitting, sometimes a walk, easy gardening, sometimes light household
activities like dusting, clearing away.
I Light physical exercise (e.g. walking, fishing, dancing).
Moderate excrrise (e.g. jogging, swimming) 1-2 hours/week.
Moderate exercise at least 3 hours per week,
d or very hard exercise regularly and several times a week, during which
physical exertion is great. Describe activities
Health History
3. Are you allergic to any foods or medications? (Please list)
4. Are you allergic to anything else? (Please list)
5. When was the last time you consumed wine, beer or other alcoholic beverages?
B Never B Less than 24 hours ago fore than 24 hours ago
6. When was the last time you took recreational drugs (e g. marijuana, cocaine, etc.),
stimulants, or sedatives?
ever B Less than 24 hours ago O More than 24 hours ago
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7. Have you slepi less than six hours last night?
Yes
8. Have you slept less than I 8 hours in total over the last three days?
Yes
9. Is there a chance you might be pregnant?
7 No 7 Yes
10. Have you had any surgery in your lifeii ?
1 No Yes
If so, please specify: e rol -
11. Have you ever had or do you have: (Please check all that apply)
7] Skin conditions/sensitive skin
1 Hearing problems -
71 Dizziness or vertigo (feeling of movernent)
0 Seizures
Strokes / Transien-t ischermic attacks
Head injury
si on problems
0 Fainting/blackouts
[r eadaches71 Parkinson's disease
lI Memory loss
P Bronchitis
7I Emphysema
F]Chronic pulmonary disease
71Abnormal heart rhythms (palpitations, arrhythmia)
71 Angina or ches: pain
1High blood pressure
Low blood pressure
Congestive heart failure or fluid in lungs
Heart rIurmur
Diabetes
Anemia
71 Asthma
71 Shortness of breath
71 Tuberculosis
71 Pacemaker/Defibrillator
71 Heart attack
E-{gnin in calves with
walking
71 Puffy ankles (edema)
71 Rheumatic fever
7 Thyroid problems
7 Cancer
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D Gastrointestinal bleeding
Fitomach problems (nausea)
D Liver disease (cirrhosis)
, Gall bladder problems
Ulcers
D Hepatitis
L Kidney disease
13. Have ypu gained or lost weight over the last year?
ONo El Yes
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ExIT QUESTIONNAIRE, WEARABLE WIRELESS CARDIAC MONITOR l/1
Personal Information
Subject ID Number:
General Questions
1. How comfortable was the wearable wireless cardiac monitor?
Very comfortableEl Somcwhat comfortable
Neither particularly comfortable, nor particularly uncomfortable
Somewhat uncomfortable
Very uncomfortable
2. Please share with us anything about the comfort/discomfort of wearing the device that
might help us improve its design.
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CRC Protocol #: 608 Evaluation of a Wearable Wireless Cardiac Monitor
Nursing Flow Sheet
P: George C. Verghese Contact Info: 617-253-4612
Co-Investigator: Thomas Heldt Contact Info: 617-324-5005
DATE )y~
Consent signed
',' Time of Last Meal/ Snack: 9 AM Should be at least 2 hours post meal.
[ Tempj' BP ( P ( _R
4 Height (no shoes) cm Weight with light clothing kg
rief Nursing Assessment:
Administer and review health questionnaire
Study procedures
[~] Prepare Skin:
* Shave
* Abrade
0 Alcohol
E44ffix Board with leads @ 4the intercostals space
[]-ape Battery
EjAffix Leads
toban Lead wires ar waist
['Don T shirt ]Aply 2 chest bands [ o-eoban wires around waist
[?Apply Pulse Ox to finger: tape
[aXSply Finger BP cuff: tape EWrist transducer (insert gauze)
Apply Sling
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Subject P _ a -
Study Procedures: Work S:
Procedure
LNITJbr7alib tion
Supine : 5min Start
SIT up quickly-+rest
1 min--Calibrate
Sit Up Quickly:5min
Stand Up-rest
1 min-*Calibrate
Stand up: 5 min max
Rest 1 min-+Calibrate
Pseudo Hop: 1 min max
Rest 1min-+Calibrate
Move Lt /Rt Arm in
plane: max 1 min
start V
Stop V-
Minutes Comments/Observations
1 18, C,
a 5.
Rest 1 min-+Calibrate
Valsalver 10 seconds Stat _+I
Stop
Rest I min -+ Calibrate
Treadmill walk: 4 mph Start |
Max Speed SStart
Stop
Treadmill increase
slowly to run:7 mph
Max Speed
Rest 2 min-+end
Calibrate
Stepping: 1 min Max
Rest 1 min-*end
Calibrate
Final Calibration
Stop Recorder
Stop Board
I,
IMax:MPH
30: 5 .
is *3 -o '____34
#Strides/Seconds
Investigator Signature Date Date
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Sub ject
1~ dminister exit questionnaire
Erxit BP (l P RPI'
Comments ; V vC '
/1
Signature (if Date 1o0i /O
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